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ABSTRACT 
 
PREMA MENEZES 
 
 Is there a trial effect in HIV clinical trials? 
 Identifying who participates in clinical trials and assessing the effect of trial 
participation on the response to highly active antiretroviral therapy 
(Under the direction of William C. Miller, MD, MPH, PhD) 
 
 
There is a widespread belief, that participation in a clinical trial provides an 
additional benefit called a trial effect. In HIV infection this claim appears to have 
been unexamined and therefore is unsubstantiated. Evidence of a trial effect may be 
confounded by systematic differences between trial and non trial participants. 
Women, minorities and heterosexuals represent an increasing proportion of HIV 
infected persons but are reportedly underrepresented in clinical trials. We examined 
if gender/sexual orientation or race/ethnicity differed by trial participation and if there 
was a trial effect in HIV clinical trials. 
 
 Using the UNC CFAR HIV/AIDS Clinical Cohort we conducted a cross 
sectional study of 738 antiretroviral treatment naïve HIV positive adults. Of these, 
30% initiated highly active antiretroviral therapy (HAART) in 13 different clinical 
trials. Subjects were characterized as trial participants if HAART was initiated in a 
clinical trial. Heterosexual men and women participated in trials at the same rate as 
men who have sex with men (PR 0.79, 95% CI 0.57, 1.11 and PR 0.97, 95% CI 
iv  
0.94, 1.66 respectively). Blacks were slightly less likely than non blacks to participate 
in clinical trials (PR 0.80, 95% CI 0.60, 1.06). 
 
This lack of substantial race/ethnicity and gender differences between groups 
supported our further investigation of a trial effect. For this analysis virologic success 
was assessed within strata of early (1996-1999) and current (2000-06) HAART 
periods and was defined as a plasma HIV RNA ≤400 copies/ml at six months post 
HAART initiation. Trial participants initiating HAART in the early period were more 
likely to achieve virologic success than non trial participants (RR 1.33; 95% CI 1.15, 
1.54), but this difference was not observed in the current period (RR 0.98; 95% CI 
0.87, 1.11).  
 
We found no difference in participation rates between women contrasted with 
men and a small insignificant difference for blacks contrasted with non blacks. In the 
current HAART period, both trial and non trial participants were equally likely to 
achieve virologic success suggesting that there is no evidence for a trial effect. 
These results suggest that data from HIV clinical trials can be generalized to clinical 
practice.
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 CHAPTER ONE - OVERVIEW 
 
Human immunodeficiency virus (HIV) infection is a pandemic representing 
a global health challenge. The introduction of highly active antiretroviral therapy 
(HAART) has made HIV a chronic (long-term), but usually manageable condition. 
Clinical trials have unequivocally demonstrated the efficacy of HAART for the 
treatment of HIV and data from these trials have been used to guide all aspects 
of HIV care and treatment1-15. However, clinical trials include selected patient 
volunteers and are conducted in a medical and social environment created by the 
trial which likely differs from routine clinical care in several aspects including 
patient characteristics and health care provision bringing about a trial effect16-20. 
A trial effect may result in improved outcomes for trial participants compared to 
non trial participants decreasing the generalizability of clinical trials data and 
questioning the soundness of the data as the basis for HIV care and treatment 
guidelines.     
  
Our primary goal was to determine whether a trial effect exists in HIV 
clinical trials by comparing outcomes among trial and non-trial participants. 
Systematic differences between these groups might lead to improved outcomes 
for one group relative to another and this might be erroneously identified as a trial 
effect17, 18. HIV clinical trials have frequently been criticized for under enrolment 
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of minorities, women and heterosexuals21-25. Gender and race are associated 
with socio economic status which can influence health related behavior and the 
course of disease. Therefore, in order to truly attribute a trial effect to trial 
participation alone, we must first ensure that the racial/ethnic gender and sexual 
orientation distribution of trial and non-trial participants is comparable  
 
What are the implications of a trial effect in HIV clinical trials? Evidence 
suggesting that trial participants have better outcomes than those who do not 
participate in HIV clinical trials could have important implications for clinical care. 
At the very least clinical care would need to be modified to incorporate some of 
the components of a trial effect, such as protocol effect which refers to the way 
treatments are delivered and a care effect which covers the incidental aspects of 
care17, 18. Currently, clinical care tends to be highly individualized whereas clinical 
trials are strictly protocol driven. It is possible that a protocol driven approach to 
HIV clinical care would result in achieving similar improved outcomes in routine 
care. An incidental aspect of care in clinical trials is frequent, closely-spaced-in-
time study visits irregardless of need. This may be contrasted with a quarterly 
visit schedule observed in routine clinical care. Incorporation of the frequency of 
study visits into clinical care could result in better provider-patient relationships 
leading to improved medication adherence and the improved outcomes 
associated with clinical trials. A trial effect may influence interpretation of clinical 
trials data and suggests that these data may be more applicable to medical and 
social environments similar to those in which the trial was conducted. 
3 
Despite the importance of a trial effect, it has received very little research 
attention in HIV infection. We were unable to identify any study that had 
examined a trial effect in HIV clinical trials. For this dissertation, we examined a 
trial effect in HIV clinical trials and whether this effect could be attributed to 
differences in gender/sexual orientation or race/ethnicity between trial and non 
trial participants.   
 
1.1 Aim One 
Aim One:  To determine if HIV clinical trial participants differ from non-trial 
participants with respect to demographics (gender/sexual orientation and 
race/ethnicity).  
 
Hypothesis: Clinical trial participants are more likely to be non black, male and 
men who have sex with men.  
 
Rationale: In both National Institutes of Health AIDS Clinical Trial Group (ACTG) 
and pharmaceutical sponsored clinical trials the enrollment of   men vs. women 
and persons of Caucasian ethnicity vs. other racial/ethnic groups is greater. 
ACTG 5095 and Gilead 934 enrolled 19% and 13.5% women respectively and 
both these trials were large multi-center studies conducted throughout the United 
States4, 7. Unpublished data from the University of North Carolina (UNC) Center 
for AIDS Research (CFAR) HIV/AIDS clinical cohort (UCHCC) suggests that 
ethnicity may be a predictor in enrollment of patients in clinical trials.  
4 
1.2 Aim Two 
 
Aim Two: To determine if there is evidence for a trial effect in HIV clinical trials. 
 
Hypothesis: Antiretroviral treatment naive HIV positive subjects who initiate 
HAART within a clinical trial will have greater virologic success six months after 
treatment initiation than non-trial participants after controlling for differences in 
baseline characteristics.    
 
Rationale: Although no studies of HIV infection have examined a trial effect there 
is some evidence from other medical specialties that such an effect might exist20, 
26-31
. Our empiric clinical observations suggest that more trial participants will 
achieve response to HAART due to positive benefits associated with a ‘trial 
effect’ such as a care effect and a protocol effect. 
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 CHAPTER TWO - BACKGROUND 
 
2.1. HIV clinical trials and HAART 
Worldwide there are 38.6 (33-46) million people living with HIV and in 2005 
alone there were 4.1 (3.4-6.2) million new HIV infections1. The advent of HAART has 
dramatically changed the HIV landscape decreasing mortality and morbidity.  
 
2.1.1 Evidence for the efficacy of HAART 
The evidence in support of HAART efficacy comes largely from clinical trials. 
The first clinical trial to establish the superiority of triple drug regimens for the 
treatment of HIV was the seminal Merck 035 study2. Preliminary data from this 
study, presented in early 1996 showed that 90% of chronically infected patients 
treated with two nucleoside inhibitors (zidovudine and lamivudine) and a protease 
inhibitor (indinavir) achieved undetectable plasma HIV RNA levels through 24 weeks 
of follow up and these results were sustained to week 52. The AIDS Clinical Trials 
Group (ACTG) 320 study also provided convincing support of this treatment 
combination3. This large study of 1156 subjects, followed for a median duration of 38 
weeks, was halted early by the Data Safety Monitoring Board, citing the clear clinical 
superiority of the three drug combination in decreasing the progression to AIDS, 
death from AIDS and increasing viral suppression. These trials heralded the advent 
of combination therapy, specifically the use of three antiretroviral drugs as standard 
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of care for the treatment of HIV. Combination therapy with three or more 
antiretroviral drugs then became referred to as highly active antiretroviral therapy 
(HAART). Since then, numerous studies conducted by the NIAID-supported ACTG 
and by the pharmaceutical industry have validated these observations4-13. Today the 
treatment of HIV infected persons with non HAART regimens would be unethical.    
 
The years following the Merck 0352 and ACTG 3203 studies have seen the 
conduct of numerous clinical trials providing a broad spectrum of data on HIV 
treatment and resulting in the continuous evolution of HIV treatment guidelines. 
Since 1996, the International AIDS Society-USA (IAS-USA) has published revised 
antiretroviral therapy guidelines seven times, most recently in August 200614.  In 
2006 the United States (US) Department of Health and Human Services (DHHS)15 
and the British HIV Association16 published updated guidelines of which drug 
combinations may be considered  first line HAART regimens for treatment naïve 
persons. A change in the new guidelines with regard to HAART provision was the 
inclusion of a specific boosted protease inhibitor (fosamprenavir/ritonavir) 
combination. This recommendation was based on data from the KLEAN5 trial 
demonstrating non-inferiority of fosamprenavir/ritonavir to the comparator drug, 
clearly showing the rapid influence of clinical trials data in the formulation of 
treatment guidelines within and outside the US.  
 
Data from HIV clinical trials has been used to guide other aspects of HIV care 
such as when to start HAART, when to change a regimen, and recommendations for 
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the use of resistance tests.  Several clinical trials have used baseline resistance 
testing prior to study entry to guide HAART selection. Two such studies, the 
TORO117 and TORO2 18 trials enrolled approximately 1000 treatment experienced 
persons at over 100 centers worldwide. Baseline resistance testing prior to study 
entry was used to guide selection of a HAART regimen to be combined with or 
without study drug. These and other trials have provided indirect support of the 
clinical benefit of resistance testing prior to the selection of new HAART for 
treatment experienced persons. Data from these trials persuaded the British HIV 
association19 to recommend resistance tests for new HAART selection in treatment 
experienced persons . Likewise, the DHHS15 recommends resistance testing for 
treatment experienced persons, citing evidence from several trials including the 
VIRADAPT20 trial where genotypic testing was found to have significant benefit on 
virologic response when choosing a new HAART regimen. 
  
 Clinical trials data is not just used to establish care and treatment guidelines, 
but is used by clinicians in clinical practice to provide evidence based care. 
Pharmaceutical companies use this data to support the superiority of a particular 
drug or combination of drugs and to directly influence patients and providers 
behavior.  However, study participants may differ substantially from the general HIV 
infected population suggesting that clinical trials data has limitations and should be 
interpreted with caution.  
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2.2. The limitations of HIV clinical trials data. 
 
  Although randomized clinical trials (RCT) provide the best evidence in support 
of treatment efficacy, there are several limitations when using clinical trials data to 
make population level/policy decisions and individual/clinical care decisions.  The 
applicability of clinical trials data may be limited because trial populations differ 
substantially from the general HIV infected population and/or because of an effect of 
trial participation that is independent of individual patient/participant characteristics.  
 
2.2.1 Clinical trial populations differ from non trial populations. 
The distribution of HIV by race, gender and transmission category has 
changed. Several epidemiologic shifts have occurred in the US in HIV infection over 
the last several years: 1) The HIV epidemic now disproportionately affects people of 
color. Of the estimated 184,991 adult and adolescent HIV infections diagnosed 
during 2001-2005, more (51%) occurred among blacks than among all other 
racial/ethnic populations combined21. The  2005 US census22 showed that African 
American (AA) and Hispanic women comprised only 24% of all women in the US, 
yet in that same year 64% of all women living with HIV/AIDS were AA compared with 
19% white and 15% Hispanic23. 2) Heterosexual intercourse has emerged as one of 
the major routes of HIV acquisition. Of all HIV/AIDS cases diagnosed in 2005 high 
risk heterosexual contact accounted for 32%23. When stratified by gender, 80% of 
the newly diagnosed women reported high risk heterosexual intercourse as the route 
for acquiring HIV infection. 3) Early in the epidemic relatively few women were 
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diagnosed with HIV infection. Today, women account for more than one quarter of 
all new HIV diagnoses, and HIV infection is the leading cause of death for AA 
women between the ages 25-34, and the third leading cause of death for ages 35-44 
surpassed only by heart disease and cancer23.  
 
Race/ethnicity, gender, and HIV transmission category can influence the 
pharmacokinetics and response to HAART24, 25.  Efavirenz clearance is strongly 
associated with race, and lower rates of clearance have been reported in African 
Americans and Hispanics as compared to whites resulting in higher plasma 
concentrations26. Increasing plasma concentrations of efavirenz are associated with 
a trend towards increasing rates of drug discontinuation, possibly due to greater side 
effects associated with higher drug concentrations.  A possible genetic basis for the 
difference in clearance rates exists. Efavirenz is metabolized by the enzyme 
CYP2B6 and an allelic variant of this enzyme associated with higher plasma drug 
concentrations is more common in African Americans than in Caucasians27.   
 
Gender based variations in HIV infection have also been described. Despite 
HAART, gender based variations in HIV infection persist and women continue to be 
more likely than men to experience HIV disease progression after adjustment for 
race, age and route of HIV transmission28. Metabolism of antiretrovirals can differ by 
gender and  for Efavirenz, female subjects have a 25% higher area under the curve 
than male subjects29. Women are also more likely to experience side effects from 
protease inhibitors and have an increased incidence of rash and risk for 
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hepatotoxicity with Nevirapine30-32. A differential response to HAART has been 
observed among specific risk groups. An analysis of 5735 patients from the French 
Hospital Database on HIV showed that homosexual patients have a better 
immunological response than heterosexual patients and injecting drug use (IDU) 
patients and the virological response is poorer among IDU patients than among 
homosexual and heterosexual patients33.   
 
Although HAART is effective, there may be a differential efficacy among 
women, ethnic minorities and IDU patients and these groups are under-represented 
in clinical trials34-37.The ACTG 5095 clinical trial convincingly established the 
inferiority of a triple nucleoside regimen for initial HAART and is cited by the 
guidelines as providing evidence against use of this treatment combination9. Yet, in 
this large trial of over 1000 subjects only 19% were women and approximately 36% 
were non-Hispanic black.  The demographics of patients in earlier landmark trials 
such as ACTG 3203 and ACTG 38411 were 83% male, 28% black and approximately 
80% male and 34% black respectively.   Pharmaceutical sponsored studies have 
been equally unsuccessful in enrolling women and minorities. The recent Gilead 934 
study only enrolled 13.5% women and 22.5% blacks7, and ABT378/r the preliminary 
study to confirm the efficacy of lopinavir/ritonavir had 90% male and 24% black 
participants10. None of these studies reported risk factors for HIV transmission. 
However, several early trials have shown an under-representation of persons who 
acquired HIV infection heterosexually or through injecting drug use and an over 
representation of men who have sex with men38-40.  A further study involving HIV 
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infected patients receiving care at three separate ambulatory clinics in Boston City 
Hospital found that women, persons of color and those who had acquired HIV 
through injection drug use were significantly less likely to have ever participated in a 
clinical trial37.  In a probability sample of 2684 person’s non-Hispanic blacks and 
Hispanics and persons under care with private HMO’s were less likely to participate 
in clinical trials35.  
 
Thus the generalizability and external validity of results from HIV clinical trials 
is questionable due to the lower participation rates of groups of patients who might 
have differential responses to HAART.  
 
2.2.2 Reporting bias in HIV clinical trials  
 
Reporting bias may limit the generalizability of clinical trials data. Eligibility 
criteria in published reports of clinical trials are usually abbreviated due to space 
issues and therefore differ greatly from the detailed eligibility criteria available in the 
actual protocol. Gandhi et al41 applied a broad range of eligibility criteria, employed 
for entry into 32 HIV randomized controlled trials conducted by the ACTG (n= 20) 
and the Community Programs for Clinical Research on AIDS (n=12), to the Women’s 
Interagency HIV Study (WIHS), the largest cohort study of HIV infected women in 
the US. The criteria used included patient demographics, concurrent or past 
illnesses including opportunistic infections and malignancies, life expectancy, 
substance abuse, general laboratory parameters, concurrent medications and 
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pregnancy/lactation status.  Based on eligibility criteria obtained directly from the 
ACTG trial protocols, a median of 50.6% of the WIHS cohort would have been 
excluded from ACTG trial participation. However, when using eligibility criteria listed 
in published reports of these protocols a much smaller proportion (median 21.2%) of 
WIHS women would have been excluded. These findings raise several issues of 
which we highlight two 1) there is a significant discrepancy between published 
eligibility criteria and actual protocol eligibility criteria making direct application of the 
clinical trials data to clinical practice difficult. 2) a large proportion of a representative 
cohort of HIV infected women would have been excluded from trial participation 
based on eligibility criteria. The implications of these findings are there is exclusivity 
in selection of HIV clinical trial participants which suggests the applicability of clinical 
trials data to the general patient population may be limited.  
 
2.2.3 The conduct of clinical trials 
 
A large number of antiretroviral drug trials, particularly those involving new 
drugs, are undertaken by pharmaceutical companies to obtain licensing approval or 
further indications for drug use.  In these trials patients are usually required to take 
the drug or drug combination under study with little or no flexibility. By contrast, in 
clinical care drug provision is highly individualized and patients participate in 
decisions involving drug choices. Therefore, these trial designs likely do not reflect 
how drugs are used in clinical care. Another key limitation is the high frequency of 
follow-up visits in clinical trials which is rarely if ever mimicked in clinical care.  
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2.3 Trial effect: Current knowledge  
 
Despite 25 years of HIV clinical trials, the largest limitation to the use of data 
from clinical trials is the unaddressed question: “Is there a ‘trial effect’ in HIV clinical 
trials?” A trial effect is considered a benefit that trial participants experience merely 
by the act of trial participation. An experimental treatment effect, protocol effect, care 
effect, Hawthorne effect, and placebo effect are all potential components of an 
overall trial effect and we provide a brief explanation of each effect.  An experimental 
treatment effect is thought to occur when experimental treatment offered in a study 
is better than current standard of care. A protocol effect is a possible benefit arising 
from the treatment regimens and procedures that are clearly outlined in the clinical 
trials manual. A care effect arises from differences in care between trial and non trial 
participants.  Hawthorne effect is due to changes in patient or clinician behavior as a 
result of the trial. Placebo effect is thought to arise from the fact that patients 
experience intangible psychologically mediated benefits from trial participation. It has 
been hypothesized that these components of a trial effect might lead to improved 
outcomes among trial participants. The differences observed between clinical trials 
and clinical care including provision of close follow up, strict adherence to protocol 
and differences in outcomes measurement might be covered under the broad 
umbrella of a ‘trial effect’.  
 
The current state of knowledge regarding a trial effect has been summarized 
in the last ten years by four published systematic reviews (Braunhotz200142, 
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Emergency Care Research Institute [ECRI] 200243, Peppercorn 200444, Vist 2005 
[Cochrane Collaboration]45). Most of the reviews predominantly focused on cancer 
care, though some included other medical specialties such as heart disease, post 
operative care, and gynecology. None of these reviews included any HIV related 
clinical trial.  
 
None of the four reviews provided convincing evidence in support of a trial 
effect. While admitting that the evidence available is limited in breadth coming 
mainly from cancer clinical trials, Braunholtz concluded that on average clinical trials 
have a positive rather than a negative effect on outcomes42. Peppercorn et al 
suggested that there was little high quality evidence in support of trial effect in 
cancer trials44 and the Cochrane review found no strong evidence of either a harmful 
or beneficial trial effect if trial participants received similar treatments to non trial 
participants45. The Emergency Care Research Institute (ECRI) concluded that 
though patients in trials survive longer they had limited confidence in these results 
due to the small evidence base.  
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Table 1.1: Summary of the conclusions of the systematic reviews that examined a trial 
effect 
Review Year  Number 
of trials  
included 
Disease Number 
of 
patients 
in trials  
Number 
of 
patients 
not in 
trials 
Conclusions 
Braunholtz  2001 14 Cancer  
Heart 
Pulmonary 
Post-op care  
NR** NR** Weak evidence that well 
conducted trials benefit 
the participants and do 
not seem on average to 
result in harm. 
ECRI$ 2002 10 Cancer 
Heart 
1793 2654 Limited confidence in 
these results. Some 
evidence that patients in 
Phase II/III trials survive 
longer than similar 
patients not in trials. 
Peppercorn 2004 24 Cancer NR** NR** Insufficient data to 
conclude that enrolment 
in clinical trials improves 
outcomes in patients 
with cancer 
Cochrane 
Review 
2005 5 
(RCT)* 
50 
(cohort 
studies) 
Cancer/Heart 
Pulmonary 
Gynecology 
Drug abuse 
Surgery 
412* 
30,862 
 
20,246 
Results suggest that 
participation in RCTs is 
likely to result in similar 
outcomes if similar 
treatments are received 
outside a trial. 
*RCT-randomized controlled trial. Total number of patients was 412. Number in and out of 
trials was not reported; **NR-Not reported; $  Emergency Care Research Institute 
 
 
2.3.1 Summary of limitations to prior research and current research 
 
Limitations to prior research 
While all four reviews were conducted with the highest integrity they are 
subject to several limitations. First, these reviews are limited by publication bias as 
they only included published studies. The implication is if more unpublished studies 
had negative or neutral results and published studies had positive results it may over 
estimate the effect of the intervention. Second, they included both adult and pediatric 
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trials and therefore may have been unable to identify a trial effect due to the 
heterogeneity between these two populations.  Third, they compared all patients 
treated within trials to all patients treated outside trials regardless of differences in 
patient populations and in clinical interventions. This approach means we are unsure 
if the reported results truly reflect a trial effect or are due to these differences. 
Fourth, the main focus of three reviews was cancer trials. However, a trial effect 
might be disease dependent and oncology might not be the best medical specialty in 
which to study trial effect as the interventions used are frequently experimental and 
not available to the general patient population. Finally, systematic reviews are limited 
both by the quality and the strength of the data available in the original published 
study. Specifically there are limitations associated with sample sizes and outcome 
measures in the included studies. If additional requisite data is needed, it must first 
be ascertained if this is available and then requested from the authors. This is a 
labor and time intensive process and likely results in only obtaining incomplete or 
poorer quality data.  
 
Current research 
This dissertation addressed the limitations of these systematic reviews. We 
were not limited by publication bias as the primary data necessary to conduct this 
study was available through the University of North Carolina (UNC) Center for AIDS 
Research (CFAR) HIV/AIDS clinical cohort (UCHCC). We had a clearly defined 
sample size, and our outcome measurement (plasma HIV RNA) is likely one of the 
best surrogate markers of response to therapy for most diseases. The antiretroviral 
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treatments provided to the clinical trial participants were in most instances available 
to and similar in the non trial participants and were non experimental.  Since we 
conducted our own independent analysis of the primary data, our results are not 
subject to the limitations of how variables were handled or adjusted for.   
In summary, there is mixed evidence available in support of trial participation 
benefit or trial effect.  What evidence there is comes mainly from cancer trials and is 
limited in breadth, quality and quantity.  HIV infection differs appreciably from cancer 
in the chronicity of the illness, treatment options, the modes of transmission, and the 
basic biology and pathogenesis of disease. HIV treatments (HAART vs. 
radiation/chemotherapy) are, in general, less toxic, likely more effective and 
following trial termination more readily and rapidly available for clinical practice due 
to accelerated regulatory approval and expanded access programs.  These factors 
may enhance or diminish any possible clinical trials effect. There are also important 
psychosocial and stigmatization issues that make HIV uniquely different from 
cancer. These meaningful differences between HIV infection and cancer, and the 
implications of these differences in the application of clinical trials data to the care 
and treatment of the HIV infected community, strongly supported our separate study 
of a trial effect in HIV clinical trials.  
 
2.4 Implications of this research  
Positive evidence for a trial effect 
We believe this study is the first, or one of the first, to examine the question of 
trial effect in HIV clinical trials.  Evidence in support of a trial effect on antiretroviral 
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treatment outcome may result in modifications to clinical care to incorporate aspects 
of ‘trial effect’.  An incidental aspect of care in clinical trials is frequent, closely-
spaced-in-time, study visits irregardless of need. This may be contrasted with a 
quarterly visit schedule generally followed in routine clinical care. Incorporation of 
the frequency of study visits into clinical care could result in better provider-patient 
relationships leading to improved medication adherence and the improved outcomes 
associated with clinical trials. Currently clinical care is highly individualized whereas 
clinical trials are strictly protocol driven. Treatment regimens in a trial are carefully 
outlined in the trial protocol and consideration is also given to if, when and how 
deviations from protocol should be permitted. Protocol effect is another aspect of 
trial effect that might be included in clinical care.  
 
Any diminished response to HAART among non-trial participants increases 
the risk for the development of resistant virus. This is clearly an issue of great public 
health importance as increase in the prevalence of resistant virus raises the 
likelihood of transmission of resistant virus to uninfected persons, as well as the 
transmission of a resistant strain of virus to an infected person. If there is a true 
benefit to trial participation due a trial effect, it is possible that modification to clinical 
care may provide the needed parity in response to HAART between trial and non-
trial participants decreasing the likelihood for the development of resistance virus.  
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No evidence for a trial effect 
Perhaps more important than support of a trial effect is the absence of one. 
The findings of no trial effect would suggest clinical equipoise between trial and non 
trial participants and has far reaching implications. First, it would address the 
perception that participation in clinical trials confers benefits in addition to those 
derived from treatment. This has long been a widespread but unsubstantiated belief. 
Second, it would help address a major concern regarding the external validity of 
clinical trials data. Clinicians would be reassured that extrapolating treatments from 
clinical trials to clinical practice does not result in variations to treatment effects. 
Third, it reinforces the utility and applicability of treatment guidelines which are 
formulated using data from clinical trials. Fourth, it would encourage patients to 
enroll in clinical trials by suggesting there is no reduction in treatment effects in a 
trial compared to clinical practice.   
 
Knowledge of the absence of a trial effect would also enable investigators to 
enroll patients in clinical trials without over promising the benefits of trial 
participation.  The American Federation of Clinical Oncologic Societies46 maintains 
that “treatment in a clinical trial is often a cancer patient’s best option”.  However, in 
HIV care which effects over 40 million people and with that number projected to 
increase exponentially, HIV clinicians and researchers have thus far been 
inadequately equipped to make any statement regarding trial participation. This 
study will enable providers to encourage enrollment in clinical trials while being 
realistic about the potential benefits and harms associated with participation.  
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There are 40 million HIV infected persons and greater than 95% of these 
persons will begin HAART outside of clinical trials. These persons and their 
providers will no doubt be reassured about the efficacy of treatment in the absence 
of a trial effect.   
 
2.5 Trial effect in HIV treatment trials  
 
We believe that HIV provides an excellent substrate for the measurement of a 
trial effect. It is a severe but chronic illness for which excellent and well 
characterized treatments are available. There are numerous well conducted clinical 
trials of antiretroviral therapy. As already mentioned, there is a well validated easily 
available test for the measurement of HIV RNA making definitions of outcome clear 
and precise. Moreover, our ability to examine trial effect was further enhanced by the 
availability of primary patient data on a well characterized set of patients from the 
same population.  
 
In sum, we employed a systematic approach to study the evidence in support 
of a trial effect in HIV clinical trials. First, we established who participates in clinical 
trials. It has been widely hypothesized that if a trial effect exists it may largely be 
explained by the differences between trial and non-trial populations. Identifying the 
extent and magnitude of these differences is essential prior to examining whether 
there is a true outcome effect associated with clinical trials participation. In particular 
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we assessed if specific demographics (race/ethnicity and gender/sexual orientation) 
are barriers to trial participation. This is important, as clinicians need to be aware of 
which patients may not enter clinical trials, to facilitate targeted enrolment of these 
groups resulting in more heterogeneous study populations thereby increasing the 
generalizability of clinical trials data.  
 
Second, we determined if a trial effect was present in HIV treatment trials by 
assessing if trial participation alone was responsible for improved outcomes. The 
primary purpose of HAART is to achieve maximal and durable viral suppression. In 
treatment naïve persons the success of HAART is demonstrated by a decrease in 
HIV RNA of 1log by week 4 post HAART and an HIV RNA of <50copies/ml by 16-24 
weeks. However, as our study period encompassed a time when HIV RNA was 
measured using four different assays with different ranges we defined viral 
suppression as an HIV RNA of <400copies/ml at six months.  We defined our 
outcome of virologic success as having a plasma HIV RNA level ≤400 copies/ml at 
six months after HAART initiation. We controlled for baseline demographic, clinical 
and laboratory parameter differences and compared this outcome among 
antiretroviral treatment naïve persons who were initiated on HAART as part of or 
outside a clinical trial.  
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CHAPTER THREE - RESEARCH DESIGN AND METHODS 
 
3.1. Overview 
Despite widespread belief that clinical trial participation leads to improved 
outcomes, there is little empirical data in support of such a trial effect. What data 
exists comes largely from cancer trials and has been inconclusive. To address 
this unknown we conducted these analyses using the University of North 
Carolina (UNC) Center for AIDS Research (CFAR) HIV/AIDS clinical cohort 
(UCHCC).   
 
3.2. Data Source 
The University of North Carolina (UNC) Center for AIDS Research (CFAR) 
HIV/AIDS clinical cohort (UCHCC) was created with two primary objectives: 
1) to document clinical strategies, therapeutic outcomes, and socio-
demographic-behavioral risk information for use in planning effective 
research objectives, and facilitating new scientific discoveries in 
translational, clinical and behavioral HIV/AIDS research 
2) to inform clinicians of current patient status in critical components of HIV 
care such as, medication and illness history, screening tests, vaccinations 
and immune status. 
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The UCHCC is a longitudinal cohort database that has enrolled over 2000 
HIV positive trial and non trial participants. This represents over 10% of the 
HIV infected population in North Carolina. The UCHCC captures information 
from a variety of sources, including, daily electronic transfers from existing 
UNC electronic databases, medical record abstractions, in-person interviews, 
and additional data such as nucleotide sequences. The data is transferred 
nightly through a secured link from the UNC Hospital’s DB2 system to the 
UCHCC SAS/WAREHOUSE ® (version 2.2) software.  This includes 
demographic, laboratory, pathology and all clinical visit information. Critical 
HIV therapeutic and clinical trials data  not available reliably in an electronic 
format, is obtained through medical chart abstraction procedures that are 
tailored to the organization of medical records at UNC.   
 
At enrollment (which is the date that patients provide informed consent 
and HIPPA authorization to participate in the UCHCC) and prospectively at 6-
month intervals, comprehensive and standardized medical chart abstractions are 
performed by trained research staff, and include demographic and clinical data 
including all prescribed medications, viral resistance reports, diagnosed illnesses, 
and hospitalizations. A high quality of abstracted data is ensured by extensive 
preliminary training and periodic retraining of data abstractors and quarterly 
quality control checks on data collected. Implausible or out of range values are 
flagged for supervisors to check and correct/confirm. Prior to data acquisition, a 
31 
data use agreement and pledge of confidentiality must be signed by all 
investigators.  
The UCHCC has been approved by the Biomedical Institutional Review 
Board of the University of North Carolina at Chapel Hill (UNC-CH) 
 
3.3. Specific Aim one 
Using the UNC CFAR HIV/AIDS Clinical Cohort we examined if trial 
participants differed from non trial participants by either race/ethnicity or 
gender/sexual orientation.  
 
Study design  
 We used the UCHCC and conducted an analysis of baseline cross-
sectional data from a cohort of antiretroviral treatment naïve HIV positive adults 
(≥18years). The UCHCC is a comprehensive database that incorporates a wide 
array of information from various hospital medical record systems into an 
accessible, standardized computerized format.  Numerous checks and validation 
steps ensure the integrity of the data.  Of particular relevance to this study was 
the availability of detailed antiretroviral medication history including dates of use, 
and trial participation history.  In addition, laboratory results are imported 
electronically from the hospital record-keeping system eliminating human data 
entry error and allowing for accurate tracking of patients’ virologic response. 
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Study population 
The study population is antiretroviral treatment naïve HIV positive adults > 
18 years of age who received care in the UNC Infectious Diseases (ID) clinic 
between the years 1996 – 2006, and initiated HAART defined as any 
combination of three or more antiretroviral agents, or a regimen that contains a 
protease inhibitor (PI) plus a non nucleoside reverse transcriptase inhibitor 
(NNRTI) with or without additional agents.  To date, over 2000 HIV positive 
adults receiving primary HIV care at the UNC ID clinic have consented to 
participate in the UCHCC. This represents most of the UNC ID clinic and over 
10% of known HIV infected persons in North Carolina, with less than 5% refusing 
to participate. The characteristics of those declining to participate in the UCHCC 
do not differ from participants.   
The UCHCC includes one-third women (33%), and two-thirds racial/ethnic 
minorities (61% African American, 31% White, 4% Hispanic, 2% American 
Indian/Alaskan Native, and 2% Other).  Most patients acquired HIV infection 
through heterosexual contact, with 16% acquiring HIV through injection drug use, 
and 26% being men who have sex with men.  Almost one-half of the UHCC 
participants reside in rural or small urban areas (49%) and over half of the 
patients travel more than 60 miles one way to receive HIV care.  Twenty-nine 
percent have no insurance coverage at initiation of HIV care, with 42% having 
public insurance coverage (Medicare and Medicaid) , and 29% private insurance 
coverage.  The median length of follow-up for the entire cohort representing the 
time from entry to HIV care is 5.3 years (IQR; 2.9, 8.3), with an accumulated 
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8701 person-years of follow-up. The characteristics of this patient population 
resemble those of the HIV infected population in the state of North Carolina. This 
is supported in Table 2 which presents the demographics of UCHCC participants 
and that of the HIV/AIDS cases for 2006 in the state of North Carolina1. 
Moreover, six southeastern states (North Carolina, South Carolina, Mississippi, 
Alabama, Georgia, Louisiana) report demographically similar epidemics 
supporting the generalizability of these results to the southeast US2-4. 
 
Table 3.1 : Demographics of UCHCC participants and North Carolina State 
HIV/AIDS patients 
 
UCHCC participants 
2000-06 
 North Carolina State 
HIV/AIDS cases- 2002-
06 
 
 Percent  Percent 
Gender  Gender  
     Male 67    Male 70.8 
   Female 33    Female 29.2 
Race  Race  
   White 31    White 26 
   Black 61    Black 66 
   Other 8    Other 8 
Health insurance  
   Private 29 
   Medicaid/Medicare/Public 42 
   None 29 
Residence  
   Rural/Small town 49 
   Urban 51 
 
 
Main Study Variables 
 
Exposure:   
The two main exposure variable were gender/sexual orientation and 
race/ethnicity.  
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Gender/sexual orientation: Men who have sex with men (MSM) and bisexual 
men were placed in one category. However, because there were no homosexual 
females and MSM is a subset of all men, we specified a joint gender and sexual 
preference variable with three categories (females/heterosexual males/MSM) to 
clarify interpretation of coefficients in multivariable regression.  
Race/ethnicity: Race/ethnicity was categorized as black or non black.  
 
Outcome:  
Subjects were characterized as trial participants if HAART was initiated as 
part of a clinical trial. Clinical trials included AIDS Clinical Trials Group (ACTG) 
supported or industry sponsored trials and may or may not have been 
randomized, placebo controlled or blinded.   
 
Covariates:  
1. Age: Age was initially coded as a continuous variable, calculated from 
birth date to date of HAART initiation, and subsequently dichotomized into 
two categories. 
2. AIDS Diagnosis: We used the Centers for Disease Control and Prevention 
(CDC) 1993 AIDS Surveillance Case Definition5 as our guide to assign an 
AIDS diagnosis to a subject. Based on this we categorized subjects as 
Yes (1) for an AIDS diagnosis and No (0) for the absence of an AIDS 
diagnosis. This variable excluded persons with a CD4 cell count ≤200 
cells/uL. 
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3. Insurance status: Health insurance status was classified as three 
categories: private, public (including Medicare, Medicaid, and other state 
and federal programs), or none. Injection Drug Use (IDU) as a route of 
HIV acquisition: This variable was categorized as positive if there was self 
reported IDU as a risk for HIV acquisition and negative if not.  
4. Distance traveled from home to the ID clinic (miles):  This was initially 
coded as a continuous variable but did not satisfy the criteria for linearity 
and was subsequently dichotomized as ≤50 miles vs. >50 miles 
5. Time from HIV diagnosis to HAART initiation (months): This was initially 
coded as a continuous variable but did not satisfy the criteria for linearity 
and was subsequently dichotomized to ≤3 vs. >3 months.  
6. Mental Illness was dichotomized as present or absent. 
7. Substance abuse was self reported and was also dichotomized as present 
or absent.  
9. Laboratory tests.  
• Baseline alanine aminotransferase (ALT), absolute neutrophil count 
(ANC), hemoglobin and creatinine were initially coded as continuous 
variables and subsequently dichotomized as normal or abnormal. Gender 
appropriate normal ranges were accounted for when forming categories.  
• Baseline viral load: Plasma HIV RNA was transformed to the log base 10 
scale to arrive at an approximately normal distribution and retained as a 
continuous variable. 
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• Baseline CD4 cell count: Baseline CD4 count was initially coded as a 
continuous variable and subsequently categorized into two clinically 
meaningful categories (≤200 vs. >200) 
 
All of the above covariables were evaluated at baseline, which was defined as 
the date of HAART initiation, except for AIDS diagnosis, mental illness and 
substance abuse, which were evaluated at any time before and up to 14 days 
after the date of HAART initiation.  
 
For laboratory results not available on the same day HAART was initiated an 
extended baseline period was considered, with baseline values being defined as 
those closest to the day of HAART initiation within a window spanning 180 days 
before and up to 14 days after the date of HAART was started.  
 
Analytic Techniques 
 
 
Univariate analysis:  
Basic descriptive statistics (proportions, mean, median, range, standard 
deviation) were generated for all variables considered in the analysis. Visual 
summaries of histograms and box plots were used to assess if continuous 
variables were normally distributed. Variables that deviated substantially from 
normality were transformed (e.g. HIV RNA levels were transformed to the log 
base 10 scale) to arrive at an approximately normal distribution.  
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Outliers were identified for each variable and, when possible, corrected if 
inconsistent with raw data. Each variable was checked for missing values. A 
complete case analysis was used in all analyses. 
Alternate approaches to coding that appeared to be more meaningful were 
explored for each variable. For example, some continuous variables were 
categorized at meaningful cut points. Similarly, some categorical variables were 
dichotomized if necessary, while other nominal variables were transformed into 
indicator variables to avoid enforcing ordinality. 
The comparison of baseline characteristics between trial and non trial 
participants was performed using chi square test for categorical variables, t test 
for normally distributed continuous variables and Wilcoxon rank sum test for non 
normally distributed continuous variables.  
 
Bivariable Analysis:   
An unadjusted prevalence ratio (PR) and a 95% CI to assess the 
association between race/ethnicity and gender/sexual orientation and trial 
participation were calculated as follows: 
PR= A1/N1  
         A0/N0  
 
where A1, A0, N1, and N0 are defined as shown below.    
Table 3.2: Schematic for bivariate data analysis-Prevalence ratio 
Characteristics Trial=Yes Trial=No Total 
Index level  A1 B1 N1 
Referent  A0 B0 N0 
Total A• B• N• 
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Assessment of Linearity:   
Linearity of the log prevalence was assessed by 1) using a quadratic 
spline model with knots at 10th, 50th and 90th percentile and 2) a likelihood ratio 
test comparing a model that included only the variable to the model with the 
restricted splines. Variables were considered to be non linear if the quadratic 
spline curve appeared non linear and the likelihood ratio comparing the two 
models had a p value <0.05. For variables where there was disagreement 
between these two tests, a decision was made based on the quadratic spline 
curve and substantive knowledge. This preliminary analysis and substantive 
knowledge informed decisions about creation of category boundaries or whether 
to retain continuous variables in linear models.  
 
Assessment of Potential for Collinearity:  
The PR for the association between each covariate and trial participation 
was examined. A PR of ≤0.3 or ≥3 was considered a strong association. 
However no association reached these predetermined cut of levels.  
 
Multivariable analysis:   
In cross sectional studies with common outcomes use of an odds ratio is 
known to overestimate the prevalence ratio6. Therefore, in our data set where the 
proportion of those experiencing the outcome was 30% our effect estimate of 
choice was a prevalence ratio. However, when the study requires adjustment for 
multiple variables (continuous and categorical), the log binomial model which is  
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used to calculate the prevalence ratio frequently fails to converge.  Under these 
circumstances using a binomial model with a poisson distribution and robust 
error variance produces estimates that are close approximations of the 
prevalence ratios7-9. The robust variance estimator is used to correct for 
overestimation of the error term resulting from use of Poisson regression with 
binomial data10.Use of the binomial model with a poisson distribution and robust 
variance estimator does result in  confidence interval estimates that are less 
precise than a log binomial model but still close to the true confidence interval 8.   
 
Effect measure modification:  
In data analysis, effect measure modification (EMM) of the PR is detected 
when the PR is greater for one of the strata, indicating a stronger relationship. To 
identify variables for which the association between gender/sexual orientation or 
race/ethnicity and trial participation varied between different levels of potential 
effect measure modifiers, we calculated stratum-specific risk ratios across each 
category for every variable of interest. To determine if there was effect measure 
modification by a specific variable, we compared stratum-specific risk ratios to 
each other. Variables were considered to be effect measure modifiers if the chi 
square test for homogeneity had a p value   ≤0.1.   In this analysis no variable 
was identified as an effect measure modifier. 
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Assessment of Confounding:  
Confounding was assessed based on a change in estimate method, a 
directed acyclic graph and substantive knowledge. In initial multivariable models, 
we used a manual change in estimate backwards elimination procedure to 
identify the particular set of confounding variables to include in the final model11. 
We calculated the change in estimate resulting from removing the potential 
confounder from the model during the model building process using the following 
formula: 100*(adjusted – crude)/crude. A change in estimate of 10% or more was 
considered indicative of confounding. We used a directed acyclic graph to assess 
the direct and indirect causal pathways linking gender/sexual orientation and 
race/ethnicity with trial participation. Figure one shows the directed acyclic graph.  
 
Model Building: 
Our choice of covariables to be included in the final model was based on 
1) the directed acyclic graph 2) a change in estimate method and 3) a priori 
knowledge. We conducted a complete case analysis using a binomial model with 
a poisson distribution and robust variance estimator. 
 
Missingness:  
As reported above a complete case analysis was first conducted excluding 
all observations with missing data. We then assessed missingness by the three 
mechanisms identified by Little and Rubin12 i.e. missing completely at random 
(MCAR), missing at random (MAR), and not missing at random (NMAR). We  
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determined for this analysis missingness of covariables may be categorized as 
MAR as the probability of the missing value is likely independent of the value 
itself but dependent on the values of other variables in the data set.  
 
Missing data is a common problem and may lead to biased results. 
Studies have suggested that multiple imputation techniques can give more 
accurate results than complete case analysis or single imputation techniques and 
optimal results can be achieved with 3-10 imputations12-16. Therefore we 
assessed the potential effect of missing data on our effect estimates by using a 
multiple imputation method with five imputed data sets. Similar to the complete 
case analysis a poisson regression model with robust error variance was run on 
the imputed data sets.  
 
Intercooled Stata (version 9.0), Stata Corporation, (College Station, TX) 
was used for all analyses. The multiple imputation was conducted using Stata’s 
ICE program17. The ICE (imputation with chained equations) program imputes 
missing values using an iterative regression switching procedure18. The imputed 
values are obtained by sampling from the distribution of the incomplete variable, 
given the observed values and the explanatory variables included in the 
imputation model. Values for any incomplete continuous variables are obtained 
using linear regression and for categorical variables using logistic regression.  
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Summary: Specific aim 1:  
 
This aim utilized a poisson regression model with robust error variance 
estimator to examine the association between the two main exposures of 
gender/sexual orientation and race/ethnicity and the outcome of trial 
participation.  
 
3.4. Specific Aim two 
 
Using the UCHCC we determined if a trial effect exists in HIV treatment 
trials by comparing the outcome of virologic success among trial and non trial 
participants.  
 
Study design  
We used the UCHCC and conducted a retrospective cohort study of 
antiretroviral treatment naïve HIV positive adults (≥18years). 
 
Study population 
Please refer to study population, specific aim one. 
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Main Study Variables 
Exposure:  
The main exposure variable was trial participation and subjects were 
characterized as trial participants if HAART was initiated as part of a clinical trial. 
Clinical trials included AIDS Clinical Trials Group (ACTG) supported or industry 
sponsored trials and may or may not have been randomized, placebo controlled 
or blinded.   
 
Outcome:  
We defined our outcome of virologic success as having a plasma HIV 
RNA level ≤ 400 copies/mL at six months after HAART initiation.  For those 
subjects for whom plasma HIV RNA result was not available at the six month 
time point an extended period spanning five to nine months from the date of 
HAART initiation was considered.   
 
Covariables: 
1. Gender/sexual orientation (heterosexual/homosexual/bisexual): This 
variable was categorized as follows 1) men who have sex with men 
(MSM) and bisexual men 2) heterosexual men and 3) women.  
2. Race/ethnicity: This variable was initially categorized as white, black and 
other and subsequently dichotomized as black or non black.  
3. Type of HAART: To accommodate the changes in HAART regimens over 
the study period we categorized type of HAART into five different  
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categories as follows 1) A boosted protease inhibitor (PI) or two PIs 
combined with either two or three nucleoside reverse transcriptase 
inhibitors (NRTIs) 2) A nucleoside reverse transcriptase inhibitors (NNRTI) 
combined with either two or three NRTIs 3) An unboosted PI combined 
with either two or three NRTIs 4) An NNRTI and a PI with or without 
NRTIs and 5) Three NRTIs.  
4. Year HAART was initiated: The year HAART was initiated was 
dichotomized to more accurately represent the differences in antiretroviral 
treatment regimens as the early HAART period (1996-99) and the current 
HAART period (2000-06). 
 
For all other covariables please refer to, specific aim one. 
 
Analytic Techniques 
 
Univariate analysis:  
 
Basic descriptive analysis was conducted as in specific aim one. 
Differences in demographic and behavioral, clinical, access to care, treatment 
and laboratory characteristics were explored using the chi square test, t test and 
Wilcoxon rank sum test with 2-sided P values reported in all cases.  
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Bivariate analysis:   
 
An unadjusted risk ratio (RR) and a 95% CI to assess the relationship 
between trial participation and the risk of virologic success at six months post  
HAART initiation was calculated as follows: 
 
00
11
^
NA
NARR =    
 
where A1, A0, N1, and N0 are defined as shown below. 
 
 
Table 3.3: Schematic for bivariate data analysis- Risk Ratio 
 
Clinical trials VL ≤400  VL >400 Total 
Yes A1 B1 N1 
No A0 B0 N0 
Total A• B• N• 
 
 
 
Multivariable analysis:  
 
We estimated the influence of other variables on the unadjusted effect 
estimate using a generalized linear model with log link and binomial error 
distribution.   However, due to non convergence of the binomial model a Poisson 
model without an offset term and with a robust variance estimator was used to 
obtain a valid estimate of the risk ratio.   
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Effect measure modification:  
In data analysis, effect measure modification (EMM) of the RR is detected 
when the RR is greater for one of the strata, indicating a stronger relationship. To 
identify variables for which the association between trial participation and 
virologic success varied between different levels of potential effect measure 
modifiers, we calculated stratum-specific risk ratios across each category for 
every variable of interest. To determine if there was effect measure modification 
by a specific variable, we compared stratum-specific risk ratios to each other. 
Variables were considered to be effect measure modifiers if the chi square test 
for homogeneity had a p value   ≤0.1.   We accounted for any effect measure 
modifiers by including interaction terms with the main factor of interest in our 
models. 
 
Assessment of Confounding: 
 Variables that were not identified as effect measure modifiers were 
assessed as potential confounding variables. For those variables that were effect 
measure modifiers, we examined potential confounding within each strata of the 
effect measure modifier(s). During the model building process we used a change 
in estimate method to identify potential confounders. A change in estimate of 
10% or more was considered indicative of substantial confounding. 
 
 
 
47 
Model Building:  
To estimate an unbiased RR of the association between trial participation 
and virologic success, we used a backwards elimination process. The full model 
consisted of the main factor of interest, interaction terms for variables identified 
as potential effect measure modifiers, and all other variables identified as 
potential confounders. In the first step of the backwards elimination process, we 
removed from the full model any interaction terms and compared the resulting 
models using a likelihood ratio test. The interaction term was retained in the 
model if the likelihood ratio test had a p value of ≤0.10. In the next step, we 
assessed each covariate for its potential to confound the main association. The 
covariate with the largest Wald p value was removed from the model and the 
estimate from the full model was compared to the reduced model. If the change 
in the estimate was less than 10% that covariate was not considered to be a 
confounder and was dropped from the model. This elimination process was 
repeated for each covariate until the cumulative change in the RR of the 
exposure was ≥10%. 
 
Sensitivity Analysis:   
 
HIV RNA result at the six month time point was unavailable for 33% of 
subjects. The missing data were assessed to be not missing at random as the 
probability of the HIV RNA result being missing is likely dependent on the true 
value. For example subjects having missing values may be more likely to be non-
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adherent to HAART and to follow-up care and therefore not have virologic 
success.  
Sensitivity analyses were done to explore the plausible impact of this 
missing data. We conducted an extreme case analysis to obtain the upper and 
lower bounds of the RR. For this we assumed  that among the subjects with 
missing outcome, every trial participant achieved virologic success while non-trial 
participants were virologic failures; and vice versa that among the subjects with 
missing outcome, all trial participants were virologic failures while non-trial 
participants had virologic success. A second analysis assigned virologic success 
to all missing values for trial and non-trial participants and virologic failure to all 
missing values for trial and non-trial participants19, 20. In this second analysis we 
varied the proportion of subjects achieving virologic success. This additional 
information on the intermediate possibilities of the RR examined if the majority of 
effect estimates supported the results of the primary analysis. 
 
Summary: Specific aim two 
 
  This aim utilized a poisson regression model with robust error variance 
and examined a trial effect in HIV clinical trials by comparing virologic success 
among ARV naïve trial and non trial participants.   
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 HIV RNA 
U= Unmeasured variables eg. socioeconomic status 
 
Figure one: Specific Aim one  
Assessment of Confounding - Directed Acrylic Graph 
 
 
52 
 
 
 
 
 
CHAPTER FOUR - INFLUENCE OF RACE, GENDER AND SEXUAL 
ORIENTATION ON PARTICIPATION IN HIV/AIDS CLINICAL TRIALS IN THE 
HAART ERA 
 
4.1 Abstract: 
 
Background: Women, racial/ethnic minorities and persons who acquire HIV 
infection through heterosexual intercourse represent an increasing proportion of 
HIV infected persons, yet they are reportedly underrepresented in clinical trials.  
 
Objective: To determine if participation in HIV treatment trials differs by 
gender/sexual orientation or race/ethnicity.  
 
Methods: We conducted a cross sectional study of antiretroviral treatment naïve 
HIV positive adults who initiated highly active antiretroviral therapy (HAART) 
between 1996-2006 and were within the University of North Carolina Center for 
AIDS Research, HIV/AIDS clinical cohort. Subjects were characterized as trial 
participants if HAART was initiated as part of a clinical trial. Prevalence ratios 
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(PR) were estimated using binomial models with a poisson distribution and 
robust variance estimator.  
 
Results: Of 738 patients initiating HAART, 30% participated in 13 different 
clinical trials. In multivariable analysis heterosexual men and women were as 
likely to participate in these trials as men who have sex with men (MSM) (PR 
0.79, 95% CI 0.57, 1.11 and PR 0.97, 95% CI 0.68, 1.39 respectively). Blacks 
were slightly less likely than non blacks to participate in clinical trials (adjusted 
PR 0.80, 95% CI 0.60, 1.06).  
 
Conclusions: In this cohort, high rates of participation in HIV treatment trials 
were observed.  Women were well represented in these trials and the 
representation by blacks was close to that of non blacks.  In this population, we 
report some success in enrolling these underrepresented groups into clinical 
trials. 
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4.2 Introduction:  
 
Well designed randomized clinical trials remain the principal source of 
reliable evidence about treatment efficacy.  Persons living with HIV infection are 
a diverse and heterogeneous population and the ability to generalize the results 
of HIV treatment trials is directly related to how well participants in these trials 
represent the larger HIV-infected population.  Treatment guidelines are based on 
data from clinical trials, but some have expressed concern that participants in 
these trials do not reflect the overall HIV infected community1, 2.  
 
In the decade since the introduction of highly active antiretroviral therapy 
(HAART), the demographics of the HIV/AIDS epidemic in the United States (US) 
have changed.  In 2006 blacks represented 13% of the US population but 
accounted for 49% of reported AIDS cases and currently women account for 
more than one quarter of all new HIV diagnoses3.  High risk heterosexual contact 
has emerged as a major route of transmission, representing 80% of all new HIV 
diagnoses in women3.   Despite these notable increases in the rates of infection 
among blacks, women and heterosexuals, these groups are reportedly 
underrepresented in HIV treatment trials.  
 
Most studies that evaluated participation in HIV/AIDS clinical trials were 
conducted early in the HIV epidemic prior to these demographic changes and 
prior to the widespread use of HAART. These studies may therefore not 
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accurately reflect the participation of women, blacks and heterosexuals in clinical 
trials 4-9. Furthermore, these studies had conflicting and inconclusive results with 
some studies reporting women were not under represented in clinical trials, 
others disagreeing and still others unable to address this issue5-7, 9. Although, 
there appears to be greater consensus that non white persons are less likely to 
participate in clinical trials, this was not found to be the case in all studies4-9.  The 
results of a more recent study, which reported that women were more likely than 
men and blacks were less likely than whites to participate in HIV treatment trials, 
are limited as participation in trials was self reported and the influence of other 
factors (clinical and laboratory parameters) associated with HAART initiation and 
trial participation was not addressed10.  Given the changes in the face of the 
epidemic and the contradictory nature of earlier results, an updated assessment 
of trial participation is needed to inform clinicians, researchers and policy makers 
about  the generalizability of treatment trial data and whether enrollment into 
such trials achieves the goals for the inclusion of women and minorities in clinical 
trials established by National Institutes of Health (NIH) and Food and Drug 
Administration (FDA) guidelines11-13.  
 
The University of North Carolina (UNC) Center for AIDS Research (CFAR) 
HIV/AIDS clinical cohort (UCHCC) comprises over 2000 HIV-positive trial and 
non-trial patients and is one of the largest ongoing clinical cohorts in the 
southeast US. Since its inception, the UCHCC has captured the changing 
demographics of the HIV epidemic; more than one-third of cohort participants are 
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women and almost two-thirds are African American.  The UCHCC provided us 
with an opportunity to examine the influence of demographics on participation in 
HIV treatment trials.  
 
4.3 Methods:  
 
Study design:  
We performed a cross sectional study of access to care and baseline 
demographic, behavioral and clinical characteristics for trial and non-trial 
participants using the UNC CFAR HIV/AIDS Clinical Cohort. This cohort 
comprising HIV positive persons (≥18years) who receive health care at the UNC 
Hospital Infectious Disease (ID) clinic has been described previously14, 15. Over 
95% of the UNC ID clinic population has consented to participate in the UCHCC 
and non participants do not differ significantly from participants. This study was 
approved by the Biomedical Institutional Review Board of the University of North 
Carolina at Chapel Hill. 
 
Study population:   
For this analysis the study population comprised antiretroviral treatment 
naïve HIV positive subjects who received care in the UNC ID clinic between the 
years 1996 – 2006, and initiated HAART, defined as any combination of three or 
more antiretroviral agents or at least one protease inhibitor and one non 
nucleoside reverse transcriptase inhibitor. Subjects were characterized as trial 
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participants if HAART was initiated as part of a treatment trial. Treatment trials 
included NIH AIDS Clinical Trial Group (ACTG) supported or industry sponsored 
trials and may or may not have been randomized, placebo controlled or blinded.   
 
Variable Specification:   
Gender (male/female) and sexual orientation (heterosexual, homosexual 
or bisexual) were primary exposure variables. Men who have sex with men 
(MSM) and bisexual men were placed in one category. However, because there 
were no homosexual females and MSM is a subset of all men we specified a joint 
gender and sexual orientation variable with three categories (females, 
heterosexual males and MSM) to clarify interpretation of coefficients in the 
multivariable regression. Race/ethnicity was categorized as black or non black.  
 
Additional variables included Centers for Disease Control and Prevention 
(CDC) categorization of AIDS16 (excludes subjects with a CD4 <200 cells/uL if 
they had no other AIDS defining illness), mental illness, insurance status 
(Medicaid/Medicare, none and private/other), distance traveled from home to the 
ID clinic, substance use, injection drug use (IDU) as a risk for HIV acquisition and 
time from HIV diagnosis to HAART initiation. IDU and substance use were self 
reported, while date of HIV diagnosis was based on either self report or testing.  
These variables were evaluated at baseline, which was defined as the date of 
HAART initiation, except for AIDS diagnosis, mental illness and substance 
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abuse, which were evaluated at any time before and up to 14 days after the date 
of HAART initiation.  
 
Selected laboratory values that may influence initiation of HAART were 
analyzed including CD4 cell count, plasma HIV RNA level, hemoglobin, 
creatinine, alanine aminotransferase [ALT], and absolute neutrophil count [ANC].  
However, as laboratory results may not be available on the same day HAART 
was initiated an extended baseline period was considered, with baseline values 
being defined as those closest to the day of HAART initiation within a window 
spanning 180 days before and up to 14 days after the date HAART was started.  
For ALT, ANC, creatinine and hemoglobin, gender appropriate normal ranges 
were accounted for and these variables were categorized as normal or abnormal.  
 
Statistical Analyses:  
Basic descriptive statistics (proportions, mean, median, range, standard 
deviation) were generated for all variables considered in the analysis. Visual 
summaries (histograms and box plots) were used to assess if continuous 
variables were normally distributed. Variables that deviated substantially from 
normality were transformed (e.g. HIV RNA levels were transformed to the log 
base 10 scale) to arrive at an approximately normal distribution. Linearity was 
assessed using a quadratic spline model and a likelihood ratio test comparing a 
model that included only the variable to the model with the restricted splines. This 
preliminary analysis and substantive knowledge informed decisions about 
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creation of category boundaries or whether to retain continuous variables in 
linear models.  
 
Predictors of trial participation were contrasted by trial participation status 
using the Pearson χ2 test for categorical variables, the Wilcoxon sum rank test for 
non-normally distributed continuous variables, or the Student's t test for normally 
distributed continuous variables.  
 
Gender/sexual orientation and race/ethnicity were the two factors of 
interest in this analysis of clinical trial participation. All variables listed above 
under variable specification were considered as possible confounding factors and 
included in the full model.   
 
Multivariable models were fit using  a binomial model with a poisson 
distribution and robust variance estimator17-20. Separate models were fit for each 
of the primary factors of interest. Interaction was assessed between each primary 
exposure and each covariate relying on a likelihood ratio test P value < 0.1. To 
assess the impact of covariates on the estimates for our primary factors of 
interest, we constructed a multivariable model with all of the predictor variables.  
 
Missingness:  
A complete case analysis was first conducted excluding all observations 
with missing data. We then assessed missingness by the three mechanisms 
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identified by Little and Rubin21 i.e. missing completely at random, missing at 
random (MAR), and not missing at random. We determined in this data set 
missingness may be categorized as MAR, as the probability of the missing value 
is likely independent of the value itself but dependent on the values of other 
variables in the data set. We assessed the potential effect of missing data on our 
effect estimates, by using a multiple imputation method with five imputed data 
sets21-23. Similar to the complete case analysis, a Poisson regression model with 
robust error variance was run on the imputed data sets.  
 
Intercooled Stata (version 9.0), Stata Corporation, (College Station, TX) 
was used for all analyses. The multiple imputation was conducted using Stata’s 
ICE program24. 
 
4.4 Results:  
 
Sample Characteristics 
 
Between1996-2006, 738 treatment naïve persons initiated HAART.  Of 
these, 224 (30.4%) initiated HAART in 13 different clinical trials, including nine 
sponsored by the ACTG and four by pharmaceutical companies (Table 4.1). The 
mean age of study subjects was 38.5 years (sd 9.0), 31% were women, 62% 
were Black, 28% were White, 6.8% were Hispanic and almost 2% were Native 
American (Table 4.2). More women self-identified as black than did men (72% 
61 
vs. 57%). Greater than a third (37.4%) of subjects had no insurance; one quarter 
(25.6%) had public insurance (Medicaid and/or Medicare).  At baseline, 26% of 
subjects had an AIDS diagnosis, the median CD4 cell count was 157 cells/uL 
(IQR 40-345) and the mean viral load was 4.7 log10 (sd 1.0). One-half of subjects 
initiated HAART within 5 months of receiving a diagnosis of HIV. The median 
distance traveled one way to receive care at the UNC ID clinic was 47 miles (IQR 
27-71). The major risk factor for HIV acquisition was heterosexual intercourse 
(54.1%) with only 13% of subjects reporting IDU as a risk factor.  
 
Gender/Sexual Orientation and Trial Participation 
 
Trial participants differed significantly from non trial participants by 
gender/sexual orientation (p=0.02). Thirty-seven percent of all MSM, 30% of all 
heterosexual men and 24% of all women enrolled in a trial. The unadjusted 
prevalence ratios (PR) for trial participation of heterosexual men were 0.81 
(95%CI 0.63, 1.04) and for women were 0.67 (95%CI 0.50, 0.88).  
 
After adjustment for age, race, insurance status, distance traveled to 
receive care at UNC ID clinic, baseline CD4 cell counts, baseline plasma HIV 
RNA levels, months from HIV diagnosis to HAART initiation, and laboratory 
parameters (ALT, ANC, creatinine, hemoglobin), heterosexual men and women 
were almost as likely to enter HIV treatment trials as MSM (PR 0.79, 95% CI 
0.57, 1.11 for heterosexual men and PR 0.97, 95%CI 0.68, 1.39 for women).  
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The multivariable model described above showed a substantial change in the 
prevalence ratio for women compared to MSM. To evaluate which variables were 
responsible for this change, we eliminated variables one at a time from the 
multivariable model. The two variables that most accounted for the change were 
insurance status and months from HIV diagnosis to HAART initiation.  
 
The distribution of MSM, heterosexual men and women by receipt of 
HAART within 3 months of HIV diagnosis was similar (42%, 39%, 36% 
respectively) (p>0.05).  However, fewer of these women entered treatment trials 
than men (16% vs. 84%). In multivariable analysis more subjects entered trials 
three months after diagnosis than in the first three months of diagnosis (PR 1.19, 
95%CI 0.88, 1.59). When stratified by gender women were almost twice as likely 
to enter trials three months after diagnosis than in the first three months of 
diagnosis (PR 1.89, 95%CI 0.98,3.65) but this difference was not observed for 
men (PR1.02, 95%CI 0.74,1.42).  
 
More women (56%) had public insurance than MSM (14%) and 
heterosexual men (30%). Persons with public insurance were less likely to enter 
treatment trials than those with private or no insurance (PR 0.42, 95% CI 0.29, 
0.61).  
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Race/ethnicity and Trial Participation 
 
Trial participants differed significantly from non trial participants by 
race/ethnicity (p=0.001).Although blacks comprised the greater proportion (62%) 
of study subjects only 26% of them enrolled in clinical trials. In bivariable analysis 
blacks were significantly less likely to participate in treatment trials (blacks vs. 
non blacks PR 0.69 95%CI 0.56, 0.86).  
 
After adjustment for age, race, insurance status, distance traveled to 
receive care at UNC ID clinic, CD4 cell count, plasma HIV RNA levels, months 
from HIV diagnosis to HAART initiation, and laboratory parameters (ALT, ANC, 
creatinine, hemoglobin), blacks remained slightly less likely to participate in 
treatment trials than non blacks  (PR 0.80, 95% CI 0.60, 1.06).  
 
Blacks had a greater delay in HAART provision than non blacks.  Two 
thirds of blacks (68%), as compared to less than a third of non blacks (32%), 
received HAART greater than three months after HIV diagnosis (p<0.001). More 
blacks had public insurance (34% vs. 14%) and fewer had private insurance than 
non blacks (30% vs. 44%) (p≤0.001). Among trial participants with private 
insurance 46% were black  and 54% were non black , and among those who had 
public insurance 83% were black and only 17% were non black (p=0.002).  
 
Table 4.3 provides the adjusted and unadjusted prevalence ratios.  
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Imputed data   
The imputed data sets produced adjusted prevalence ratio estimates that 
were generally similar to the results obtained in the complete case analysis 
(Table 4.3).  The point estimate for heterosexual men was closer to the null after 
imputation (PR 0.90; 95% CI 0.70, 1.16), while the point estimate for women was 
slightly further from the null, although the confidence interval included the null 
(PR 0.91; 95% CI 0.68, 1.22).  The point estimate for blacks was virtually 
unchanged (PR 0.78, 95% CI 0.62, 097). Overall, the confidence interval 
estimates of the imputed prevalence ratios were narrower than those obtained in 
the complete case analysis.  
 
 
4.5 Discussion 
 
Gender and race differences between trial and non trial populations may 
limit the generalizability of trial findings. In HIV infection, these differences may 
have greater importance as increasing numbers of women and minorities are HIV 
infected. While limited, there is some data, supporting a differential response to 
specific antiretroviral’s in women and minorities25-28. In this analysis, blacks were 
less likely to participate in HIV treatment trials and there was no influence of 
gender/sexual orientation on trial participation. Although in the clinic population, 
women were less likely than MSM to enter into trials as observed in the 
bivariable relationship, this association approached parity after accounting for 
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confounding variables.  For blacks compared to non-blacks, the strength of the 
bivariable estimate was decreased after adjustment, but they remained slightly 
less likely to participate in HIV treatment trials.  
 
Our finding, of no difference in participation rates between women and 
MSM, is supported by other studies in HIV infection where women were as likely 
and in some instances more likely to enroll in trials than men5, 7, 10. A five year 
review of women’s participation in clinical trials by the US FDA found that overall 
women participate in clinical trials at almost the same rate as men29. Perhaps 
guidelines and policies adopted both in the US and other countries to correct 
years of gender imbalance in trial participation are finally coming to fruition13, 30.  
Likewise, compared with MSM participation rates for heterosexual men though 
slightly lower were also not significantly different. This contrasts with earlier 
observations that heterosexual men were underrepresented in clinical trials8. Our 
results suggest that, in our setting, both gender and sexual orientation do not 
significantly influence participation in HIV treatment trials. When such differences 
are observed, the influence on these results of other factors, such as geographic 
location, type of trial, and study site, needs to be evaluated.  
 
In unadjusted analyses, women were less likely than MSM to participate in 
HIV treatment trials, but with adjustment the difference was markedly diminished. 
The two variables that were most responsible for this change in estimate were 
insurance status and months from HIV diagnosis to treatment. More women had 
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health insurance (public or private) than men and almost one half of all women 
had public insurance (Medicaid and/or Medicare). While not a program restricted 
to women, over two thirds of adults (≥18 years) on Medicaid are women31, 32. To 
qualify for Medicaid, women must meet defined category and income 
requirements. Categories include being pregnant, being the mother of a child 
under 18, or having a disability; additionally all categories have income 
limitations31, 33. Over one half of the women in our study were under 40 years of 
age and consequently likely to be pregnant, rearing a child or both.  Although 
having HIV/AIDS is a Medicaid defined disability, one study reported that in North 
Carolina women comprised 47% of all HIV infected Medicaid beneficiaries34. 
Having health insurance provides women with access to treatment, care and 
other health benefits and may limit their need to participate in clinical trials.  
 
The number of months from HIV diagnosis to treatment was the second 
variable associated with changing the adjusted effect estimate between women 
and trial participation. For all subjects, but especially for women trial participation 
was more likely to occur when HAART was delayed for greater than three 
months after diagnosis.  Conceivably, a three month period may be needed to 
conduct the rigorous screening, consent and enrollment procedures required for 
trial participation. In our study, twice as many women trial participants received 
HAART three months after HIV diagnosis than in the first three months. In 
general, untreated HIV infected women have an approximately 0.2 log lower viral 
load than men35.  This difference in baseline viral load was also observed in our 
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study cohort. Reportedly women may also delay entry into care by more than 
three months after receiving an HIV diagnosis36. Because women voluntarily or 
involuntarily delayed receipt of HAART, it may have provided opportunity for 
investigators to encourage enrollment, provide counseling on trial specific 
aspects, such as the need for contraception, and arrange for assistance with 
familial obligations, such as child care. Therefore, we suspect that the 
combination of two effects - 1) a delay in receipt of HAART appeared to increase 
participation and 2) women were more likely to delay receipt of HAART - were at 
least partly responsible for our results.  
 
Although, in the crude analysis blacks were less likely than non blacks to 
participate in trials, the strength of this association diminished when accounting 
for other variables and the adjusted absolute difference (8%) was even smaller 
(data not shown).  These  results, though similar to other HIV related studies 
suggesting blacks were less likely than either Caucasians or other ethnicities to 
enter clinical trials, are also dissimilar in that though a difference was observed, it 
was not substantial and could partially be explained by adjustment for other 
variables4-6, 9. Possibly additional adjustment for unmeasured variables, such as 
socioeconomic status, might have further diminished this observed difference.  
 
Research in other areas has shown that participation rates for blacks can 
be comparable or higher than other races and we feel that our results reflect a 
trend supporting decrease in disparities for black enrolment into trials  37, 38.  
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However, as we included only HIV treatment trials and in our study more subjects 
without insurance were black this might have influenced our results. The UNC ID 
clinic has a high proportion of black patients, but there are likely other reasons 
why the difference we observed was small including lack of clinician bias in 
referral and enrolment of patients into trials and strong patient provider trust. A 
major barrier to blacks participating in HIV treatment trials is not being asked to 
participate and in fact a systematic review of health research studies showed that 
when invited to participate blacks were as likely and sometimes more likely to 
participate in research1, 38. Provider endorsement of trials, provision of clinical 
trial information by providers and trust in providers is associated with trial 
participation5, 39-41.  
 
Since our data represent a single clinic population, these results may not 
be generalizable to other settings or parts of the country.  However, as the 
UCHCC comprises about 10% of all HIV infected individuals in NC, it is probably 
representative of the HIV population in NC. Moreover, six southeastern states 
(North Carolina, South Carolina, Mississippi, Alabama, Georgia, Louisiana) 
report demographically similar epidemics supporting the generalizability of these 
results to the southeast US42-44. The comparability of enrolment between blacks 
and non blacks and between genders and those of different sexual orientations 
may partly be attributed to the demographic make up of the ID clinic and to the 
existing ACTG. Previous studies have shown that, compared to other ACTG 
sites, the UNC ACTG has high trial enrolment rates for racial/ethnic minorities, 
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and for women trial participation is associated with living in an area with a NIH or 
CDC supported research network10, 45 . In addition, NC has historically had strict 
eligibility criteria for the state funded AIDS Drug Assistance Program (ADAP). 
Limited access to ADAP may leave participation in HIV treatment trials as the 
only option for access to antiretroviral therapy.    
 
In summary, we found that in the clinical setting studied, blacks can and 
will participate in HIV treatment trials at similar rates to non blacks and women 
are as likely as men to participate in these trials. An exploration of barriers to 
clinical trial participation must look beyond demographics to other factors 
including awareness and information about clinical trials and trial characteristics. 
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Table 4.1: Description of Clinical Trials in which subjects in this study 
were enrolled, 1996-2006 
 
 
 
 
 
 
 
 
Study  N Percent Study Treatments  
ACTG 384 34 15.18 ZDV/3TC + EFV   
   
ZDV/3TC +  NFV 
   
ddI/ d4T + EFV  
   
ddI/ d4T + NFV 
   
ZDV/3TC + EFV + NFV 
   
ddI/ d4T + EFV + NFV   
ACTG 388 10 4.46 ZDV/3TC + IDV 
   
ZDV/3TC + IDV + EFV  
   
ZDV/3TC + IDV + NFV 
A5015 6 2.68 d4T + FTC + LPV/ RTV   
A5073 6 2.68 FTC+TFV + LPV/RTV 
   
FTC + d4T + LPV/ RTV 
A5095 51 22.77 ZDV/3TC/ABC  
   
ZDV/3TC + EFV 
   
ZDV/3TC/ABC + EFV 
A5142 25 11.16 ZDV (or d4t XR) + 3TC + EFV 
   
ZDV (or d4t XR) + 3TC + LPV/RTV 
   
EFV + LPV/RTV 
A5164 19 8.48 
The study provided ARVs including LPV/r,d4T and 
TDF/FTC but clinicians were free to use any 
standard ART. 
A5175 8 3.57 ZDV/3TC + EFV   
   
ddI/FTC + ATV 
   
FTC/TFV + EFV 
A5202 36 16.07 FTC/TFV + EFV  
   
ABC/3TC + EFV 
   
FTC/TFV + EFV 
   
FTC/TFV + ATV/ RTV 
Abbott M97 9 4.02 d4T + 3TC+ LPV/RTV 
Gilead 903 12 5.36 d4T + 3TC + EFV 
   
TDF + 3TC + EFV 
Gilead 934 1 0.45 FTC/TFV + EFV  
   
ZDV/3TC + EFV 
KLEAN 7 3.13 ABC/3TC + FPV/RTV  
   
ABC/3TC + LPV/RTV 
Total 224 100 
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Table 4.2: Baseline sample characteristics comparing trial participants to  
non-trial participants, 1996-2006 
 
 
 Total Non Trial Trial p 
value* 
 N(738) % N (514) % N (224) %  
Demographic and 
Behavioral Characteristics 
       
Age (years)        
<40   429 58.1 300 58.4 129 57.6 0.84 
>40 309 41.9 214 41.6 95 42.4  
Gender/sexual preference        
MSM1/Bisexual men     252 34.2 160 31.1 92 41.1 0.02 
Heterosexual men 260 35.2 183 35.6 77 34.4  
Heterosexual women 226 30.6 171 33.3 55 24.6  
Race        
Black       455 61.7 337 65.6 118 52.7 0.001 
Non Black   283 38.3 177 34.4 106 47.3  
IDU2 as HIV risk         
No 642 87 435 84.6 207 92.4 0.004 
Yes 96 13 79 15.4 17 7.6  
Substance Abuse        
No  627 85 436 84.8 191 85.3 0.87 
Yes 111 15 78 15.2 33 14.7  
Access to Care 
Characteristics 
       
Insurance Status        
Public3 191 25.9 162 31.5 29 13.0 0.000 
None 276 37.4 176 34.2 100 44.6  
Private/Other 258 35.0 170 33.1 88 39.3  
Distance to ID4 clinic (miles)        
<50     182 24.7 123 23.9 59 36.3 0.1 
>50 527 71.4 390 75.8 137 61.2  
Clinical Characteristics 
       
AIDS5 Diagnoses        
No  546 74 387 75.4 159 71 0.22 
Yes 192 26 127 24.6 65 29  
CD4 cells/uL        
≤200    321 43.5 200 38.9 121 54 0.02 
>200 246 33,5 176 34.2 70 31.3  
Mean HIV RNA (log10) (sd) 4.7 (1.0) 4.7 (0.95) 4.7 1.03 0.88 
Mental Illness        
No  654 88.6 454 88.3 200 89.3 0.14 
Yes 84 11.4 60 11.7 24 10.7  
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Diagnosis to treatment 
(months) 
       
≤3   250 33.9 195 37.9 55 24.6 0.2 
       >3 393 53.3 289 56.2 104 46.4  
Other Laboratory 
Parameters 
       
ANC6 (109/L)        
Normal 348 47.2 223 43.4 125 55.8 0.2 
Abnormal 221 30 130 25.3 91 40.6  
Hemoglobin (g/dL)        
Normal 258 34.9 152 29.6 106 47.3 0.14 
Abnormal 311 42.1 202 39.3 109 48.7  
Creatinine (mg/dL)        
Normal 685 93.1 469 91.3 216 96.4 0.008 
Abnormal 51 6.9 44 8.6 7 3.1  
7ALT U/L        
Normal 451 61.1 276 53.7 175 78.1 0.88 
Abnormal 100 13.6 61 11.9 39 17.4  
 
* p values comparing trial to non trial participants 
1MSM=Men who have sex with Men; 2IDU=Injection Drug Use; 3Public insurance= 
Medicaid/Medicare; 4 ID= University of North Carolina Infectious Disease; 
5AIDS=Acquired Immune Deficiency Syndrome; 6ANC=Absolute Neutrophil Count 
7ALT=Alanine aminotransferase 
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Table 4.3: Unadjusted, adjusted and imputed prevalence ratios and 95% 
confidence intervals for trial participation by gender/sexual orientation and 
race/ethnicity 
 
  
Prevalence Ratios (95%Confidence Interval) 
  
Unadjusted 
 
Adjusted 
 
Adjusted Imputed 
 
Gender/Sexual Orientation* 
     
 
MSM/Bisexual     
men     1.0  1.0  1.0  
 
Heterosexual  
men 0.81 (0.63, 1.04) 0.79 (0.57, 1.11) 0.89 (0.69, 1.15) 
 
Heterosexual 
women 0.67 (0.50, 0.88) 0.97 (0.68, 1.39) 0.87 (0.65, 1.18) 
 
Race/Ethnicity**       
 
Non Black        1.0  1.0  1.0  
 
Black 0.69 (0.56,0.86) 0.80 (0.60,1.06) 0.78 (0.62,0.97) 
 
MSM= Men who have sex with men 
Non Black= White, Hispanic, Native American and other. 
 
* adjusted for age, race,  insurance status, distance traveled to receive care at UNC ID 
clinic, baseline CD4 cell counts, baseline HIV RNA levels, months from HIV diagnosis to 
HAART initiation, ALT, ANC, creatinine, hemoglobin 
 
** adjusted for age, gender/sexual orientation,  insurance status, distance traveled to 
receive care at UNC ID clinic, baseline CD4 cell counts, baseline HIV RNA levels, 
months from HIV diagnosis to HAART initiation, ALT, ANC, creatinine, hemoglobin 
 
 CHAPTER FIVE - DOES HAART EFFICACY TRANSLATE TO EFFECTIVENESS? 
EVIDENCE FOR A TRIAL EFFECT. 
 
5.1 Abstract:  
 
Background: There is a widespread belief, that participants in clinical trials 
experience   improved outcomes due to a trial effect. Yet, in HV infection this claim 
appears to have been unexamined and therefore is unsubstantiated.  
 
Objective: To determine whether a trial effect exists in HIV treatment trials by 
comparing virologic success among antiretroviral (ARV) naïve trial and non-trial 
participants who initiated highly active antiretroviral therapy (HAART). 
 
Methods: This analysis included ARV naïve subjects who initiated HAART between 
1996-2006. Subjects were characterized as trial participants if HAART was initiated 
in a clinical trial and virologic success was defined as a plasma HIV RNA ≤400 
copies/ml at six months post HAART initiation. Virologic success was assessed 
within strata of early (1996-1999) and current (2000-06) HAART periods. Risk ratios 
(RR) were estimated using binomial models with a poisson distribution and robust 
variance estimator. 
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Results: The virologic success of trial participants contrasted with non trial 
participants differed by the period in which HAART was initiated (p=0.001). Trial 
participants initiating HAART in the early period were significantly more likely to 
achieve virologic success than non trial participants. (adjusted RR 1.33; 95% CI 
1.15, 1.54), but this difference was not observed in the current period (adjusted RR 
0.98; 95% CI 0.87, 1.11).  
 
Conclusions: We found no strong evidence supporting a trial effect in HIV 
treatment trials in the current HAART period suggesting the results of these trials are 
relevant to comparable HIV infected patients.   
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5.2 Introduction:  
 
Patients who participate in clinical trials are thought to have better outcomes 
than those who do not, due to a trial effect. Yet, there is limited evidence that such a 
trial effect exists, and to date there appears to be no study in HIV infection 
examining such an effect.   
 
A trial effect may arise due to a treatment effect (newer, better or 
experimental treatments available to trial participants but unavailable outside the 
trial),  protocol effect (differences in the way treatment regimens are delivered), care 
effect (differences in care), Hawthorne effect (behavior change secondary to being 
under observation) and placebo effect (“psychologically mediated” benefits that arise 
due to being in a trial)1-4.   
 
Several studies in oncology, cardiology, psychiatry, and surgery have 
examined the hypothesis that trial participation improves outcomes and five reviews 
have summarized the results of these studies with varied conclusions1, 3, 5-7. While 
the  largest review found no strong evidence of either a harmful or beneficial trial 
effect, previous reviews have concluded that patients in trials survive longer and that 
there was weak evidence that well conducted trials tend to benefit the participants1, 6, 
7
.  More recently, Peppercorn et. al. reported there was little evidence in support of 
trial participation leading to improved outcomes3. These reviews included both 
pediatric and adult studies, but the influence on the results of the diversity in these 
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populations was not addressed. In most reviews the predominant studies were 
cancer related, where unlike current HIV infection, survival is an important outcome.  
Some reviews compared patients within trials to those not in trials regardless of 
differences between interventions or subjects, therefore it is unclear whether these 
results truly reflect a trial effect1, 3, 5, 6. Additionally, these reviews are subject to all 
the constraints of systematic reviews such as publication bias. Notably, none of the 
five reviews included any HIV clinical trial. 
 
Our primary goal is to determine whether a trial effect exists in HIV treatment 
trials by comparing virologic success among antiretroviral (ARV) naïve trial and non-
trial participants who are initiated on highly active antiretroviral therapy (HAART). A 
trial effect in HIV clinical trials could have important implications.  The benefit of 
HAART is unquestionable, but if a trial effect results in a difference in the magnitude 
of benefit for trial participants there are implications for clinical care. At the very 
least, clinical care may need to be modified to incorporate aspects of trial effect such 
as protocol effect or care effect to achieve similar results. A trial effect might argue 
for the reduced applicability of clinical trials data to non-trial participants and 
clinicians would need to exert caution when extrapolating this data to the general 
HIV infected population. Finally, the basis for the care and treatment guidelines of 
HIV infected persons is clinical trials data and a trial effect might raise the question 
of different sets of guidelines for trial and non-trial participants.   
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Differences in characteristics between trial and non-trial participants may lead 
to differences in outcomes between these groups and this might erroneously be 
identified as a trial effect. The University of North Carolina (UNC) Center for AIDS 
Research (CFAR) HIV/AIDS clinical cohort (UCHCC) comprises over 2000 HIV-
positive trial and non-trial patients. This cohort provided us with the opportunity to 
address differences between these groups and to investigate the evidence for a trial 
effect in HIV clinical trials. 
 
5.3 Methods:  
 
Study design:  
 
We conducted a retrospective cohort study using the UCHCC. This cohort 
comprising adult (≥18years) HIV positive persons who receive health care at the 
UNC Hospital Infectious Diseases (ID) clinic has been described previously8, 9. Over 
95% of the UNC ID clinic population has consented to participate in the UCHCC and 
non participants do not differ significantly from participants. This study was approved 
by the Biomedical Institutional Review Board of the University of North Carolina at 
Chapel Hill.  
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Study population:   
 
Antiretroviral naïve HIV positive adults who initiated HAART between 1996-
2006 were included in this analysis. HAART was defined as any combination of 
three or more antiretroviral agents, or at least one protease inhibitor (PI) and one 
non nucleoside reverse transcriptase inhibitor (NNRTI). Subjects were characterized 
as trial participants if HAART was initiated as part of a clinical trial. Clinical trials 
included NIH AIDS Clinical Trial Group (ACTG) supported or industry sponsored 
trials.  
 
Variable Specification:  
 
We defined our outcome of virologic success as having a plasma HIV RNA 
level ≤ 400 copies/mL at six months from the date of HAART initiation, using a 
window of five to nine months and selecting the plasma HIV RNA value nearest six 
months if more than one value occurred in this window.   We considered trial 
participation as the factor of interest.  
 
Sexual orientation (heterosexual/homosexual/bisexual) and gender were 
considered jointly and resulted in a variable with three categories -1) men who have 
sex with men (MSM) and bisexual men 2) heterosexual men and 3) women. Race 
was categorized as black or non black. Additional variables included insurance 
status (Medicaid/Medicare, none and private/other), distance traveled from home to 
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the ID clinic in miles and the duration  in month’s from the date of HIV diagnosis to 
HAART initiation.    
 
Selected clinical laboratory values that may influence trial participation and 
initiation of HAART including CD4 cell count, plasma HIV RNA level, hemoglobin, 
creatinine, alanine aminotransferase [ALT], and absolute neutrophil count [ANC] 
were analyzed at baseline which was defined as the day HAART was initiated.  For 
laboratory results not available at baseline an extended window spanning 180 days 
before and up to 14 days after the date HAART was initiated was considered. ALT, 
ANC, creatinine and hemoglobin were categorized as normal or abnormal and 
gender appropriate normal ranges were accounted for. 
 
Treatment characteristics included type of HAART and the date HAART was 
initiated. HAART was categorized as 1) a ritonavir-boosted PI or two PIs combined 
with either two or three nucleoside reverse transcriptase inhibitors (NRTIs) 2) a 
NNRTI combined with either two or three NRTIs 3) an unboosted PI combined with 
either two or three NRTIs 4) a NNRTI and a PI with or without NRTIs and 5) three 
NRTIs. The year HAART was initiated was dichotomized to more accurately 
represent the differences in initial treatment regimens as the early HAART period 
(1996-99) and the current HAART period (2000-06). 
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Statistical Analysis: 
 
Differences in demographic, clinical, treatment and laboratory characteristics 
were explored using the chi square test, t test and Wilcoxon rank sum test with 2-
sided P values reported in all cases.  
 
We estimated an unadjusted risk ratio (RR) and a 95% Confidence Interval 
(CI), to assess the relationship between trial participation and the risk of virologic 
success at six months after HAART initiation. The influence of other variables on the 
unadjusted effect estimate was assessed using a Poisson model with a robust 
variance estimator10-12.   Regression analysis with interaction terms between the 
relevant covariates was used to assess for effect measure modification. Variables 
were considered to be effect measure modifiers if the coefficient estimate for the 
interaction term differed significantly from zero (p ≤0.1). This analysis indicated a 
significant interaction between trial participation and the period in which HAART was 
initiated.  
 
A backward elimination procedure was used to arrive at the final model. 
Confounding was evaluated by both substantive (a priori) and change in estimate 
criteria. A covariate was retained as a confounding variable if it changed the effect 
estimate by at least 10 percent.  The variable type of HAART did not change the 
effect estimate by ≥10% but was included in one of the two final models based on 
substantive knowledge.   
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For our primary analysis we conducted a complete case analysis using a 
Poisson model with a robust variance estimator.  
 
Sensitivity Analysis:   
 
HIV RNA result at the six month time point was unavailable for 33% of 
subjects. The missing data were assessed to be not missing at random as the 
probability of the HIV RNA result being missing is likely dependent on the true value 
of this result13. For example, subjects having missing values may be more likely to 
be non-adherent to HAART and therefore not have virologic success.  
 
Sensitivity analyses were done to explore the impact of the missing data.  We 
conducted an extreme case analysis to obtain the upper and lower bounds of the 
RR14-16. For this we assumed that among the subjects with missing outcome, every 
trial participant achieved virologic success while non-trial participants were virologic 
failures and vice versa.  A second analysis assigned virologic success to all missing 
values for trial and non-trial participants and virologic failure to all missing values for 
trial and non-trial participants14-16.  In this second analysis we varied the proportion 
of subjects achieving virologic success. This additional information on the 
intermediate possibilities of the RR examined if the majority of effect estimates 
supported the results of the primary analysis15, 16.   
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Intercooled Stata (version 9.0), Stata Corporation, (College Station, TX) was 
used for all analyses. 
 
5.4 Results:  
 
Sample Characteristics: 
 
Of the 738 ARV naïve persons initiating HAART, 67% had an HIV RNA result 
available at the six month time point. The mean age of study subjects was 38.5 
years (standard deviation 9.9), 37.3% were women, 60.1% were Black, 27.4% were 
White, and 8.3% were Hispanic (Table 5.1). When comparing subjects who achieved 
virologic success to those who did not there were no differences by age, 
gender/sexual orientation (p=0.9), race (p=0.1), insurance status (p=0.7) CD4 cell 
count (p=0.6) and baseline HIV RNA (RR 0.96 per log10 increase, 95% CI 0.92, 1.00; 
p=0.06) 
 
Description of trials 
 
Subjects participated in 13 different clinical trials, nine sponsored by the 
ACTG and four by pharmaceutical companies (Table 5.2) 17-30. Both the specific 
aims and the study designs for these trials varied widely. Ten trials had a 
randomized design and of these, six were open label, two were double blind, and 
two were partially blinded18, 19, 21-29.  The remainder three trials were non randomized 
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and open label17, 21, 30. Most trials (n=11) were Phase III or IV.   Two ACTG and one 
industry sponsored trial enrolled subjects in the early, and seven ACTG and three 
industry sponsored trials enrolled subjects in the current HAART periods 
respectively.  
 
HAART regimens 
 
Predictably HAART regimens differed substantially between the early and 
current HAART periods (p<0.001). Unboosted PI regimens were initiated in over 
one-half (53%) of subjects in the early period, but in only 15% of subjects in the 
current period.  By contrast, in the current HAART period more persons were 
initiated on an NNRTI based regimen (45%) followed by a boosted PI based regimen 
(27%). The majority of subjects initiating an NNRTI regimen received efavirenz 
(85%) while the majority of those initiating a boosted PI regimen received 
lopinavir/ritonavir (70.8%). Of the 134 subjects who received unboosted PI 
regimens, 64% were initiated on nelfinavir.  The most commonly used 
nucleoside/nucleotide backbone was lamivudine/zidovudine (49.7%), followed by 
lamivudine/stavudine (14.7%), tenofovir/emtriciatbine or lamivudine (13.8%), and 
lamivudine/abacavir (7%).  
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Virologic success: 
 
The proportion of subjects achieving virologic success in this cohort was high 
(78%, 95%CI 74-82%). Both trial and non-trial participants had high rates of virologic 
success (86%, 95%CI 79-91% for trial; 74% 95%CI 69-79% for non-trial 
participants). Overall, in unadjusted analysis, trial participants were 16% more likely 
to achieve virolgoic success when compared to non-trial participants (RR 1.16, 
95%CI 1.06, 1.27).  
 
Sample characteristics contrasted by period (early vs. current) of HAART initiation: 
 
To examine the influence of baseline differences between subjects on our 
results, we compared subjects across the period (early vs. current) of HAART 
initiation. Participation in clinical trials was higher in the current than in the early 
HAART period (39.4% vs. 23%, p<0.001). Baseline plasma HIV RNA levels (median 
4.7log10 vs. 4.8 log10, p=0.9) did not differ between these periods, but more subjects 
had a CD4 cell count >200 cells/uL in the current period (52% vs. 38%, p=0.006). 
The insurance status of study subjects differed considerably between these periods 
with more subjects having no insurance (40% vs. 24%) and fewer having public 
insurance (23% vs. 32%) in the current than in the early period (p=0.003). No 
interval differences in gender/sexual orientation (p=0.9), mean age (p=0.6) and 
distance traveled to the ID clinic (p=0.2) were observed.  
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Primary (Complete Case) Analysis: 
 
The virologic success contrasting trial and non-trial participants differed by the 
period in which HAART was initiated (p=0.001) (Table 5.3). In bivariable analysis 
trial participants initiating HAART in the early period were significantly more likely to 
achieve virologic success than non-trial participants (RR 1.42, 95%CI 1.24, 1.62) but 
a similar difference was not observed in the current period (RR 1.07, 95%CI 0.95, 
1.19) . After adjustment trial participants in the early period remained more likely to 
achieve virologic success than non-trial participants (RR 1.33; 95% CI 1.15, 1.54). 
By contrast, in the current period, there was no difference in virologic success 
between trial and non-trial participants (RR 0.98; 95% CI 0.87, 1.11).  
 
Missing Data:  
 
The outcome of virologic success measured by an HIV RNA result within the 
specified 5-9 month window was unavailable for 242 (33%) subjects. Of these, over 
one-half (56.6%) were in the current HAART period. Subjects with missing HIV RNA 
result were similar to those not missing this result in terms of age (mean age 37 vs. 
39 years), race (65% vs. 60% black) and gender (29% vs. 31% female). Likewise, 
we found no differences in clinical characteristics (baseline HIV RNA and CD4 cell 
count) and laboratory parameters (ALT, ANC, creatinine, hemoglobin) (all p values 
>0.05). However, more subjects missing HIV RNA result had no insurance (45% vs. 
34.6%) and fewer had private insurance (27.6 vs.39.5) (p=0.004). Among subjects 
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with missing outcome more were non-trial participants (77% vs. 23%, p <0.001). 
When stratified by HAART period, we found no difference in the proportion of trial 
versus non-trial participants missing the outcome for the early period (p=0.1), but a 
difference was observed for the current period with more non-trial participants 
missing the outcome (p=0.03).  
 
Sensitivity analysis: 
 
Sensitivity analyses were conducted to assess the impact of the missing data 
on our effect estimate (Tables 5.4 and 5.5). For those subjects missing HIV RNA 
result, we assumed virologic success for trial participants and virologic failure for 
non-trial participants and obtained an upper bound for the RR of 1.89 for the early 
HAART and 1.40 for the current HAART periods. Conversely, when assuming that 
all trial participants had virologic failure and non-trial participants had virologic 
success a lower bound of the RR for the early and current HAART period of 1.17 
and 0.83 respectively was obtained. In a second analysis, where all subjects missing 
data were considered to be virologic failures a RR of 1.75 for the early and 1.19 for 
the current HAART periods was obtained. In the early period, all the sensitivity 
analyses that were performed supported greater virologic success for trial 
participants with the lowest rate of virologic success being 17%. In the current period 
our sensitivity analyses showed that at a 70% or lower rate of virologic failure there 
was no difference between trial and non trial participants. 
 
92 
5.5 Discussion:  
 
To our knowledge, this is the first study to examine a trial effect in HIV clinical 
trials by comparing virologic success among ARV naïve trial and non-trial 
participants initiating HAART. The results of our primary analysis showed that in the 
early HAART period (1996-99), there was a beneficial effect to trial participation. 
Both in bivariable and multivariable analysis, trial participants were significantly more 
likely to achieve virologic success than non-trial participants. However, in the current 
HAART period (2000-06) we found no difference in virologic success comparing trial 
to non-trial participants.  
 
The demographics and HIV disease status of subjects in the early and current 
HAART periods was comparable. Therefore, we believe, that our results reflect the 
noteworthy improvements in ARV therapy between these periods.  Other cohorts 
examining the efficacy of triple combination therapy have reported chronological 
improvements in viral suppression31, 32. Like other studies, we observed changes in 
the initial HAART regimen with a significant increase in the use of a boosted PI or 
NNRTI and a decline in the use of an unboosted PI 31.  The superiority of NNRTI and 
boosted PI versus unboosted PI regimens in ARV naïve persons has been clearly 
demonstrated19, 33, 34 . Other improvements to ARV therapy include increased 
tolerability and decreased pill burden and frequency.  Moreover, calendar time may 
also be associated with other unmeasured factors such as provider experience, 
medication adherence and increased patient awareness about the benefits of and 
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improvements to HAART. The period in which HAART was initiated likely acted as a 
surrogate for these temporal factors.   
 
 A beneficial effect to trial participation was observed in the early HAART 
period, suggesting a trial effect. Results from cancer trials have suggested a trial 
effect in trials conducted before 1986, a time of rapid change for cancer care and 
treatments3. This might also be the case in our study where during the early period 
trial participants might have experienced a treatment effect. In this period there were 
differences in the type of HAART with more trial participants initiated on an NNRTI 
/PI combination and more non-trial participants initiated on an unboosted PI regimen 
(data not shown).   However, even after controlling for potential differences in the 
type of HAART, the beneficial effect of trial participation persisted.  Although, 
suggestive of a trial effect, these results may also be attributed to unmeasured 
characteristics such as medication adherence where trial participants in this period 
may have had higher virologic success due to better medication adherence.  
 
We found no strong evidence supporting a trial effect in the current HAART 
period. Earlier studies have reported higher rates of virologic suppression for clinical 
trials, and this has been of concern as viral suppression is associated with better 
outcomes and decreased development of drug resistant virus 35. The efficacy of ARV 
therapy is likely a function of patient, drug and virus related factors. Patients want 
treatments that are convenient and tolerable, clinicians want treatments that can 
suppress viral replication. The results of our study suggest that in the current period 
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HAART achieves these goals of convenience, tolerability and viral suppression. The 
assumption thus far has been, that the improved outcomes experienced by trial 
participants relative to non-trial participants are due to 1) patient selection biases 
(healthier patients in clinical trials) 2) the trial effect and 3) to intrinsic differences 
between trial and non-trial participants which are beyond socioeconomic, health or 
other measurable differences1-3, 5, 7, 36.   However, our results suggest that, 
regardless of measured or unmeasured differences between trial and non-trial 
participants, HAART is equally effective both in a clinical practice and in a clinical 
trial setting. Our definition of virologic success (plasma HIV RNA value ≤400 
copies/ml at six months) may have limited our ability to detect a trial effect in the 
current period.  Possibly a longer outcome period, might have favored trial 
participants and supported a trial effect. In the current period, all but one of the trials 
included in our study was a Phase III or later trial therefore we feel that these results 
are most applicable to Phase III or later trials.  
 
Lack of a trial effect has important public health implications.  First, it 
demonstrates that irrespective of the setting, HAART achieves viral suppression 
which is known to result in immune reconstitution, decrease in opportunistic 
infections and improved quality of life making HIV infection a chronic long-term 
illness. However HIV infection differs from other chronic illnesses in co-morbidities, 
treatments, and psychosocial issues. Consequently we need to advocate for and 
implement a HIV specific chronic care model.  Second, in our study the efficacy of 
HAART was no different from the effectiveness. This suggests that the results of 
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clinical trials are generalizable to the larger HIV infected population. Third, clinicians 
and public health officials can have confidence that treatment guidelines that are 
formulated based on clinical trials data, are relevant to routine clinical care and that 
data from these trials can be extrapolated to clinical care.  
 
The large proportion (33%) of this cohort who were missing the outcome of 
virologic success at the six month time point is concerning. Reassuringly, subjects 
with missing data were similar to those for whom complete data was available. 
Sensitivity analyses were conducted, to determine the influence of the missing data 
on effect estimates obtained in our primary analysis.  In an intention to treat analysis 
where all missing data was assigned virologic failure trial participants in the early 
and current periods were more likely to achieve success. We varied the proportion of 
virologic failures and found that, irrespective of the proportion of failures, in the early 
period trial participants remained more likely to achieve virologic success. By 
contrast, in the current period at a 100% rate of virologic failure there was a modest 
(20%) benefit to trial participation. This benefit to trial participation was not observed 
at a 70% rate or lower rate of virologic failure.  These analyses substantiate the 
results of the primary analysis and suggest that the exclusion of subjects with 
missing data did not bias our results.  
 
We examined potential sources of bias that could either mask or create a trial 
effect37, 38. We defined virologic success based on a single measurement, to 
minimize bias due to possible differences in measurement frequency between trial 
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and non-trial participants. In our study, care setting bias and clinician selection bias 
appear less likely since all subjects were followed at the UNC Infectious Disease 
Clinic and received their health care from a single group of physicians who were 
both principal investigators and health care providers1, 3.  We addressed potential 
confounding arising from differences in baseline characteristics between the groups 
by fitting a fully adjusted model with all the variables and found similar results for the 
fully adjusted and the more parsimonious final model. A limitation to these 
comparisons, is we are unable to control for unmeasured confounders such as the 
above mentioned medication adherence or socio-economic status. However, the 
efficacy of HAART in the current period suggests less emphasis may be placed on 
unmeasured confounders.  
 
Although, we found no trial effect, there are advantages to participation in 
clinical trials. These include access to 1) free treatments 2) follow up by a dedicated 
team of study personnel 3) close monitoring for potential side effects or adverse 
events 4) free health assessments and 5) monetary compensation.  In keeping with 
other studies, we did not observe worse outcomes for trial participants in either 
period39-43. Therefore, we feel a reasonable corollary, is that trial participation does 
not increase the risk of a bad outcome. Though, there may be a difference in the 
magnitude of the observed benefit conferred by trial participation, most studies 
appear not to refute that a positive benefit exists 1, 36, 44. A frequently unrecognized, 
but important benefit provided by trial participation, is patients are able to use the 
study team as a support group and a coping strategy. Lastly, there is an inherent 
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altruism involved in trial participation which affords patients’ a sense of pride and self 
worth which is immeasurable45-48.  
 
In sum, we found no strong evidence supporting a trial effect in HIV clinical 
trials in the current HAART period. Therefore, the message is clear; regardless of 
setting or patient characteristics HAART is effective.  Rather than detracting from the 
utility of clinical trials, our results support the position that well conducted 
randomized HIV clinical trials remain one of the best ways to demonstrate the 
efficacy of an intervention or treatment, and that the results of such trials are 
generalizable.  
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Table 5.1: Baseline sample characteristics comparing trial participants to 
non-trial participants, restricted to complete cases, 1996-2006 
 Total No  
Trial  
Trial  p 
value* 
 N (496) % N=327 % N=169 %  
Virologic Success 
       
HIV RNA ≤400 c/mL 327 65.9 242 74 145 85.8 0.003 
HIV RNA >400 c/mL 169 34.1 85 26 24 14.2  
Demographic and 
Behavioral Characteristics 
       
Age (years)        
 <40   273 55 183 56 93 53.3 0.6 
>40 223 45 144 44 79 46.7  
Gender/sexual preference        
MSM/Bisexual men     175 35.3 101 30.9 74 43.8 0.02 
Heterosexual men 136 27.4 114 34.9 51 30.2  
Heterosexual women 185 37.3 112 34.2 44 26.0  
Race        
Black       298 60.1 211 64.5 87 51.5 0.005 
Non Black     198 31.9 116 35.5 82 48.5  
Substance Abuse        
No  327 65.9 212 64.8 118 69.8 0.3 
Yes 169 34.1 115 35.2 51 30.2  
Access to Care 
Characteristics 
       
Insurance Status        
Public 126 25.9 103 31.8 23 14.1 0.001 
None 168 34.6 96 29.7 72 44.2  
Private/Other 192 39.5 124 38.4 68 41.7  
Distance to ID clinic (miles)        
<50   130 26.3 77 23.6 53 31.4 0.06 
>50 365 73.7 249 76.4 116 68.6  
Clinical Characteristics 
       
AIDS Diagnoses        
No  343 69.2 233 71.3 110 65.9 0.2 
Yes 153 30.8 94 28.7 59 34.1  
CD4 cells/uL        
<200    257 57.6 151 54.1 106 63.4 0.1 
200-350        81 18.2 53 19.0 28 16.8  
>350 108 24.2 75 26.9 33 19.8  
Mean HIV RNA (log10) (sd) 4.9 (1.0) 4.7 (1.0) 4.8 (1.0) 0.6 
Mental Illness        
No  398 80.2 262 80.1 136 80.5 0.9 
Yes 98 19.8 65 19.9 33 19.5  
Diagnosis to treatment 
(months) 
       
<1   56 12.5 45 14.4 11 8.1 0.08 
1-3 112 24.9 71 22.7 41 29.9  
3-24 177 39.4 119 38.1 58 42.3  
      >24 104 23.2 77 24.7 27 19.7  
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Treatment Characteristics 
       
HAART Initiation Year        
1996-99 161 32.5 124 37.9 37 21.9 0.001 
2000-06 335 67.5 203 62.1 132 78.1  
HAART category        
n2pib/n3pib/n2pi2 99 20.0 39 11.9 60 35.5 0.001 
n2nnrti/n3nnrti 192 38.7 132 40.4 60 35.5  
n2pi/n3pi 134 27.0 116 35.4 18 10.7  
n2nnrtipi/nnrtipi 40 8.1 20 6.1 20 11.8  
3nrti 31 6.3 20 6.1 11 6.5  
Other Laboratory 
Parameters 
       
ANC (109/L)        
Normal 268 62.2 173 65.3 95 57.2 0.09 
Abnormal 163 37.8 92 34.7 71 42.8  
Hemoglobin (g/dL)        
Normal 195 41.1 116 43.6 79 47.6 0.4 
Abnormal 237 54.9 150 56.4 87 52.4  
Creatinine (mg/dL)        
Normal 462 93.2 298 91.1 164 97 0.01 
Abnormal     34 6.8 29 8.9 5 3  
ALT U/L        
Normal 338 81.1 204 81.3 134 80.7 0.9 
Abnormal 79 18.9 47 18.7 32 19.3  
 
 
* p values comparing trial to non trial participants 
MSM=Men who have sex with Men; Public insurance= Medicaid/Medicare;  
 ID= University of North Carolina Infectious Disease; 
AIDS=Acquired Immune Deficiency Syndrome; ANC=Absolute Neutrophil Count 
ALT=Alanine aminotransferase 
 
HAART Category 
n2pib=2 NRTIs + boosted PI   n3pib= 3 NRTIs + boosted PI  
n2pi2= 2 NRTIs + 2 PIs   n2nnrti= 2NRTIs + 1NNRTI 
n3nnrti= 3NRTIs + 1NNRTI   n2pi= 2 NRTIs + 1 PI 
n3pi= 3 NRTIs + 1 PI    n2nnrtipi=2 NRTIs + 1PI + 1NNRTI 
nnrtipi= 1PI + 1NNRTI   3nrti= 3 NRTIs 
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Table 5.2 Description of Clinical Trials in which subjects in this study were enrolled, 
1996-2006 
 
Study  N Percent Study Treatments  
ACTG 384 34 15.18 ZDV/3TC + EFV   
   
ZDV/3TC +  NFV 
   
ddI/ d4T + EFV  
   
ddI/ d4T + NFV 
   
ZDV/3TC + EFV + NFV 
   
ddI/ d4T + EFV + NFV   
ACTG 388 10 4.46 ZDV/3TC + IDV 
   
ZDV/3TC + IDV + EFV  
   
ZDV/3TC + IDV + NFV 
A5015 6 2.68 d4T + FTC + LPV/ RTV   
A5073 6 2.68 FTC+TFV + LPV/RTV 
   
FTC + d4T + LPV/ RTV 
A5095 51 22.77 ZDV/3TC/ABC  
   
ZDV/3TC + EFV 
   
ZDV/3TC/ABC + EFV 
A5142 25 11.16 ZDV (or d4t XR) + 3TC + EFV 
   
ZDV (or d4t XR) + 3TC + LPV/RTV 
   
EFV + LPV/RTV 
A5164 19 8.48 
The study provided ARVs including LPV/r,d4T and 
TDF/FTC but clinicians were free to use any standard 
ART. 
A5175 8 3.57 ZDV/3TC + EFV   
   
ddI/FTC + ATV 
   
FTC/TFV + EFV 
A5202 36 16.07 FTC/TFV + EFV  
   
ABC/3TC + EFV 
   
FTC/TFV + EFV 
   
FTC/TFV + ATV/ RTV 
Abbott M97 9 4.02 d4T + 3TC+ LPV/RTV 
Gilead 903 12 5.36 d4T + 3TC + EFV 
   
TDF + 3TC + EFV 
Gilead 934 1 0.45 FTC/TFV + EFV  
   
ZDV/3TC + EFV 
KLEAN 7 3.13 ABC/3TC + FPV/RTV  
   
ABC/3TC + LPV/RTV 
Total 224 100 
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Table 5.3: Unadjusted and adjusted risk ratios and 95% confidence intervals for 
virologic success by trial participation within strata of HAART period 
 
 
 
  
Risk Ratios (95% Confidence Interval) 
  
Unadjusted  
 
Adjusted* 
 
Adjusted** 
 
HAART period 
      
Early (1996-99)       
No Trial 1  1  1  
Trial 1.42 (1.24, 1.62) 1.40 (1.22, 1.62) 1.33 (1.15, 1.54) 
Current (2000-06)       
No Trial 1  1  1  
Trial 1.07 (0.95, 1.19) 1.01 (0.90, 1.14) 0.98 (0.87, 1.11) 
 
 
* adjusted for age,  distance traveled to receive care at UNC ID clinic, baseline HIV RNA 
levels, months from HIV diagnosis to HAART initiation,  creatinine 
 
** adjusted for age,  distance traveled to receive care at UNC ID clinic, baseline HIV RNA 
levels, months from HIV diagnosis to HAART initiation,  creatinine, type of HAART 
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Table 5.4 Sensitivity Analysis: risk ratios  for trial participation following different 
adjustment scenarios for missing data in the early HAART period 
 
 
* adjusted for age,  distance traveled to receive care at UNC ID clinic, baseline HIV RNA 
levels, months from HIV diagnosis to HAART initiation,  creatinine 
 
 
Risk Ratios (95% Confidence Interval 
 
Unadjusted Adjusted* 
 
Assigning virologic success to missing values for trial participants and  virologic 
failure to missing values for non trial participants 
No Trial 1  1  
Trial 2.46 (1.74, 3.47) 1.89 (1.59, 2.29) 
 
Assigning virologic failure to missing values for trial participants and  virologic 
success to missing values for non trial participants 
No Trial 1  1  
Trial 0.83 (0.58, 1.19) 1.17 (1.02, 1.35) 
 
Assigning virologic failure  to all missing values in both groups 
No Trial 1  1  
Trial 1.70 (1.15, 2.51) 1.75 (1.44, 2.13) 
 
Assigning virologic failure to  80% of all missing values in both groups 
No Trial     
Trial 1.42 (1.16, 1.75) 1.47 (1.24, 1.74) 
 
Assigning virologic  failure to  70% of all missing values in both groups 
No Trial 1  1  
Trial 1.37 (1.13, 1.67) 1.46 (1.23, 1.73) 
 
Assigning virologic failure  to  60% of all missing values in both groups 
No Trial 1  1  
Trial 1.35 (1.14, 1.60) 1.40 (1.19, 1.65) 
 
Assigning virologic failure to  40% of all missing values in both groups 
No Trial 1  1  
Trial 1.36 ( 1.19, 1.55) 1.45 (1.25, 1.68) 
 
Assigning virologic failure to  20% of all missing values in both groups 
No Trial 1  1  
Trial 1.36 ( 1.19, 1.55) 1.45 (1.25, 1.68) 
 
Assigning virologic failure to  0% and virologic success to 100% of all missing 
values in both groups 
No Trial 1  1  
Trial 1.20 (0.88, 1.64) 1.27 (1.14, 1.42) 
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* adjusted for age,  distance traveled to receive care at UNC ID clinic, baseline HIV RNA 
levels, months from HIV diagnosis to HAART initiation,  creatinine 
 
 
Table 5.5 Sensitivity Analysis: risk ratios  for trial participation following different 
adjustment scenarios for missing data in the current HAART period 
 
Risk Ratios (95% Confidence Interval) 
 
Unadjusted Adjusted* 
 
Assigning virologic success to missing values for trial participants and  virologic 
failure to missing values for non trial participants 
No Trial 1  1  
Trial 1.66 (1.33, 2.07) 1.40 (1.23, 1.60) 
 
Assigning virologic failure to missing values for trial participants and  virologic 
success to missing values for non trial participants 
No Trial 1  1  
Trial 0.75 (0.60, 0.94) 0.83 (0.73, 0.94) 
 
Assigning virologic failure  to all missing values in both groups 
No Trial 1  1  
Trial 1.22 (0.96, 1.56) 1.19 (1.02, 1.40) 
 
Assigning virologic failure to  80% of all missing values in both groups 
No Trial 1  1  
Trial 1.22 (1.06, 1.41) 1.17 (1.01, 1.36) 
 
Assigning virologic  failure to  70% of all missing values in both groups 
No Trial 1  1  
Trial 1.18 (1.03, 1.34) 1.10 (0.95, 1.27) 
 
Assigning virologic failure  to  60% of all missing values in both groups 
No Trial 1  1  
Trial 1.16 (1.02, 1.31) 1.10 (0.96, 1.26) 
 
Assigning virologic failure to  40% of all missing values in both groups 
No Trial 1  1  
Trial 1.08 (0.96, 1.21) 1.03 (0.90, 1.17) 
 
Assigning virologic failure to  20% of all missing values in both groups 
No Trial 1  1  
Trial 1.08 (0.97, 1.21) 1.02 (0.90, 1.17) 
 
Assigning virologic failure to  0% and virologic success to 100% of all missing 
values in both groups 
No Trial 1  1  
Trial 1.02 (0.83, 1.25) 0.98 (0.89, 1.08) 
 CHAPTER SIX - CONCLUSIONS 
 
HIV clinical trials should involve diverse populations of patients to ensure 
external validity. However, available studies have suggested that racial/ethnic 
minorities, women and persons who acquire HIV infection through heterosexual 
intercourse are under represented in clinical trials1-5. These differences between trial 
and non trial participants are thought to undermine the generalizability of data from 
clinical trials. Additionally, as treatment guidelines are based on data from clinical 
trials, the utility and applicability of treatment guidelines to clinical practice has also 
been questioned.  
Beyond the fundamental issue of demographic differences, there is a broader 
and more important issue, namely ‘Is there a trial effect in HIV clinical trials?’.  A trial 
effect is perceived to be a benefit obtained by trial participants that results in 
improved outcomes. A trial effect may arise due to a treatment effect (newer, better 
or experimental treatments available to trial participants but unavailable outside the 
trial) or to a participation effect. This latter effect has been further subdivided into a 
protocol effect (differences in the way treatment regimens are delivered), care effect 
(differences in care), Hawthorne effect (behavior change secondary to being under 
observation) and placebo effect (“psychologically mediated” benefits that arise due 
to being in a trial)6-8.   Several studies in oncology, surgery, psychiatry and other 
medical disciplines have studied differences in outcomes between trial and non trial 
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participants. However, to date, no study has examined a trial effect in HIV clinical 
trials.  
In this dissertation we examined if trial and non trial participants differed by 
gender/sexual orientation and race/ethnicity. We further examined if there was a trial 
effect in HIV clinical trials by comparing virologic success among trial and non trial 
participants.  
 
Influence of race, gender and sexual orientation on participation in HIV 
treatment trials. 
 
Our assessment of participation in HIV treatment trials showed that blacks 
when compared to non blacks were slightly less likely to participate in treatment 
trials. We feel that our results reflect a trend supporting decrease in disparities for 
black enrolment into trials.  A recent study assessed the willingness of blacks to 
participate in HIV treatment trials and found that of study subjects only 57% had 
been invited to participate in research and 86% of those invited did participate in 
research9.  Not being informed about research or not being invited to participate in 
research has been previously cited as major reasons for blacks not to participate in 
clinical research2, 10-12.  In certain settings, health care providers may themselves be 
poorly informed about the clinical trials and this could result in potential subjects not 
being informed about the research, or principal investigators may not be practicing 
clinicians and thus are not in direct contact with subjects resulting in potential 
subjects not being invited to participate. Our success in enrolment of blacks might in 
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part be attributed to the fact that the trial investigators were also the clinicians 
providing care to the subjects and therefore both information provision and invitation 
to participate were optimized. In fact a recent study showed that when invited blacks 
were equally likely and sometimes more likely than non blacks to participate in 
clinical trials13.  
 
Lack of trust in researchers is another reason for non participation by blacks 
in clinical trials. It is not difficult to understand why blacks may have fears or 
misunderstandings about the intentions of researchers. Historically the non 
participation of blacks has been attributed to the history of racism in medical 
research exemplified by the Tuskegee Syphilis study. However, trust developed 
between a primary care provider and a patient, has been suggested to be a means 
to overcome this fear of participation in research14. In fact, this may well have been 
the case in our study. Since most if not all of the study subjects were established 
patients of the investigators, there might have been interpersonal trust which 
decreased the fear of trial participation.  
 
In keeping with other HIV trials we demonstrated that women were as likely 
as men to enroll in clinical trials. In the early 90’s the need for proportionate 
representation of women and minorities in clinical trials was mandated by law in the 
National Institutes of Health revitalization act15, 16. It is heartening, that at least for 
women in HIV clinical trials significant progress has been made towards compliance 
with this mandate.  It is worth mentioning that in our study regardless of gender 
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subjects with public insurance (Medicaid/Medicare) were less likely, while those 
without insurance were more likely to participate in trials, . This suggests that 
insurance status influences trial participation and that persons without insurance 
might perceive enrolment in a trial as a means to obtain treatment and health care. 
Clearly trial participation can provide primary care, treatment and other health 
benefits to patients who have limited resources. We must caution investigators to be 
vigilant, as insurance status not race or gender might be a bigger determinant of trial 
participation and clinical trials might become studies of the uninsured or under 
insured.   
 
In sum, we found no significant differences in trial participation rates for 
blacks compared with non blacks and for women compared with men. Clinical 
trialists must understand that successful enrolment of under represented groups can 
be enhanced by communication and trust. Investigators must communicate their 
intentions to subjects and to the community clearly, constantly and continuously 
through the study period. Moreover, it is vital for this communication to continue 
once the study has ended.  This will ensure appropriate dissemination of study 
results. Additionally, subjects will be reassured that their health and well being 
remains of interest to investigators even after study completion. Trust (interpersonal 
or institutional) is an iterative process fostered by honest and frequent 
communication.   
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Trial effect in HIV treatment trials. 
 
A trial effect has been posited to result in improved outcomes for trial relative 
to non trial participants. In the early HAART period (1996-99) trial participants were 
more likely than non trial participants to achieve virologic success. However, we are 
unable to say with confidence that this difference in virologic success is purely 
attributable to a trial effect.  Although we were able to assess the influence of 
diverse demographic, clinical, and laboratory characteristics on our results we were 
unable to assess the influence of unmeasured confounders such as medication 
adherence and socio-economic status. Therefore we conclude that in this period 
there was a benefit to trial participation which may be attributable to several causes 
including a trial effect.  
 
In the current HAART period (2000-06) we found no strong evidence 
supporting a trial effect. The importance of this finding cannot be over stated. During 
this period advancements in the treatment of HIV led to highly potent and more 
tolerable antiretroviral (ARV) treatment combinations which are equally effective 
regardless of trial participation. Therefore, at an individual level, non trial participants 
should feel secure in the knowledge that their likelihood of virologic success 
subsequent to antiretroviral treatment is no different from trial participants.  Since a 
clinical trial is by definition experimental and can result in either a beneficial or 
harmful outcome, trial participants can be reassured that they are unlikely to 
experience a harmful outcome of virologic non response.  
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Lack of a trial effect has overarching public health implications. An evidence 
based approach to patient care requires that the results of well designed clinical 
trials be incorporated into clinical practice. However, the widely held belief that a trial 
effect improves outcomes for trial participants has led clinicians and public health 
advocates to express reservations about extrapolating these results to clinical 
practice. Our finding of no trial effect should reassure both these groups as it 
suggests that results of HIV treatment trials can be applied to other HIV infected 
persons. It also supports the validity of the treatment guidelines which are 
formulated based on data from clinical trials. Clinicians can have more confidence 
that these guidelines are relevant to routine clinical care and that data from these 
trials can be extrapolated to their patient populations.  
 
Rather than being perceived as a discouragement, the absence of a trial 
effect should encourage patients to enroll in clinical trials. Many trials do offer 
participants advantages. In certain situations, for example the treatment of patients 
with resistant HIV, or for highly ARV experienced patients trials might provide newer 
and more effective treatments that are unavailable as standard of care. Patients in 
trials interact one-on-one and frequently with a dedicated team of study personnel 
which fosters trust in the providers and belief in the trial intervention leading to better 
adherence. Other benefits associated with trial participation include careful 
monitoring, free health care and laboratory assessments and sometimes 
compensation. Patients also experience both pride and self worth from the 
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knowledge that they are contributing to science and to improving the lives of other 
HIV infected persons.  
 
Randomized clinical trials are critical to the advancement of HIV treatment 
and care. The absence of a trial effect should be perceived as strong support that 
well designed and conducted clinical trials provide valid and generalizable 
information and should neither hinder enrolment into nor conduct of clinical trials. 
Patients who are considering participation in a trial should be clearly informed about 
the potential benefits and risks of the intervention being compared in the trial and 
about other options that may be available. Investigators and clinicians should be 
cautious about over promising the potential outcomes from trial participation. 
However, these caveats notwithstanding, we feel that both patients and clinicians 
can recognize the crucial role of clinical trials in the advancement of knowledge.   
 
Perhaps, the single most important message that the absence of a trial effect 
highlights, is that  HAART efficacy does translate into effectiveness. Regardless of 
the setting, HAART achieves durable and sustained suppression of HIV replication. 
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APPENDIX ONE – CHAPTER FOUR 
 
Table A1.1: Unadjusted, adjusted and imputed prevalence ratios and 95% confidence 
intervals comparing trial participants to non-trial participants by baseline 
demographic, access to care and clinical characteristics 
 
 Prevalence Ratios (95% Confidence Interval) 
 Unadjusted  
 
Adjusted * 
 
Adjusted imputed*  
Demographic and Behavioral Characteristics 
Age (years)    
 <30   1 1 1 
30-39 0.88 (0.62, 1.25) 0.86 (0.60, 1.23) 0.88 (0.65, 1.17) 
40-49 0.98 (0.68, 1.41) 1.12 (0.78, 1.63) 1.03 (0.76, 1.40) 
>50 0.85 (0.53, 1.38) 0.85 (0.51, 1.41) 0.93  (0.62, 1.39) 
Gender/sexual preference    
MSM/Bisexual men     1 1 1 
Heterosexual men 0.72 (0.51, 1.01) 0.87 (0.62, 1.22) 0.95 (0.73, 1.25) 
Heterosexual women 0.76 (0.57, 1.03) 1.01 (0.70, 1.43) 0.91 (0.67, 1.23) 
Race    
Black       1 1 1 
White     1.38 (1.03, 1.85) 1.21 (0.88, 1.67) 1.26 (0.97, 1.63) 
Other 1.61 (1.09, 2.37) 1.27(0.87, 1.86) 1.29 (0.95, 1.75) 
IDU as HIV risk     
No 1 1 1 
Yes 0.55 (0.33, 0.90) 0.61 (0.35, 1. 03) 0.61 (0.39, 0.97) 
Access to Care Characteristics 
Insurance Status    
Public 1 1 1 
None 2.39 (1.58, 3.61) 1.99 (1.23, 3.24) 1.99 (1.35, 2.92) 
Private/Other 2.25 (1.48, 3.42) 1.97 (1.18, 3.30) 1.78 (1.19, 2.67) 
Distance to ID clinic (miles)    
<25     1 1 1 
 25-50 0.92 (0.57, 1.37) 0.90 (0.63, 1.27) 0.92 (0.66, 1.28) 
>50 0.74 (0.44, 0.98) 0.84 (0.61, 1.15) 0.83 (0.61, 1.12) 
Clinical Characteristics 
   
Diagnoses to treatment(months)    
<1 1 1 1 
1-3 2.19 (1.18, 4.08) 1.85 (1.00, 3.41) 2.04 (1.21, 3.43) 
3-24 2.37 (1.31, 4.29) 2.14 (1.18, 3.87) 2.38 (1.45, 3.90) 
>24 1.61 (0.85, 3.05) 1.75 (0.92, 3.32) 1.77 (1.02, 3.06)  
CD4 cells/uL    
<200    1 1 1  
200-350        0.84  (0.58, 1.23) 0.92 (0.61, 1.38) 0.85 (0.61, 1.18) 
>350 0.69 (0.47, 1.00) 0.82 (0.53, 1.26) 0.72 (0.47, 1.10)  
HIV RNA (log10) 0.99 (0.86, 1.15) 0.87 (0.76, 0.99) 0.92 (0.82, 1.04) 
* adjusted for all variables in this table  and for mental illness, substance abuse, baseline 
absolute neutrophil count, hemoglobin, creatinine and ALT 
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TABLE A1.2: Unadjusted and adjusted prevalence ratios and 95% confidence 
intervals comparing trial participants to non-trial participants for selected 
baseline characteristics stratified by gender 
 
 
 
                                               Prevalence Ratios (95% Confidence Interval) 
 Women Men 
 Unadjusted  Adjusted  Unadjusted  
 
Adjusted 
 
Access to Care Characteristics* 
Insurance Status     
None  1 1 1 1 
Public 0.39  
(0.21, 0.70) 
0.44 
(0.23, 0.86) 
0.48  
(0.30, 0.79) 
0.44  
(0.21, 0.92) 
Private/Other 0.97 
(0.58, 1.62) 
 0.97  
(0.54, 1.74) 
0.93  
(0.72, 1.21) 
0.92  
(0.27, 1.96) 
Clinical Characteristics** 
Diagnosis to 
treatment (months) 
    
<3  1 1 1 1 
>3 2.15  
(1.10, 4.02) 
1.89 
(0.98, 3.65) 
1.02 
(0.74,1.40) 
1.02 
(0.74, 1.42) 
     
*adjusted for age, race,  distance traveled to receive care at UNC ID clinic, baseline CD4 
cell counts, baseline HIV RNA levels, months from HIV diagnosis to HAART initiation, ALT, 
ANC, creatinine, hemoglobin 
 
 
** adjusted for age, race, insurance status, distance traveled to receive care at UNC ID 
clinic, baseline CD4 cell counts, baseline HIV RNA levels, months from HIV diagnosis to 
HAART initiation, ALT, ANC, creatinine, hemoglobin 
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APPENDIX TWO – CHAPTER FIVE 
 
 
Table A.2.1: Baseline sample characteristics comparing early and current HAART 
periods, restricted to complete cases 
 Total Early period 
1996-99 
Current period 
2000-06 
p 
value* 
 N(496) % N(161) % N(335) %  
Primary Exposure 
       
No Trial 327 65.9 124 77 203 60.6 0.001 
Trial 169 34.1 37 23 132 39.4  
Demographic and Behavioral Characteristics 
Age (years)        
 <40   273 55 91 56.5 67 54.3 0.6 
>40 223 45 79 43.5 42 45.7  
Gender/sexual preference        
MSM1/Bisexual men     175 35.3 54 33.5 121 36.1 0.9 
Heterosexual men 136 27.4 55  34.2 110 32.8  
Heterosexual women 185 37.3 52  32.3 104 31.1  
Race        
Black       298 60.1 107 66.5 191 57 0.04 
Non Black     198 31.9 54 33.5 144 43  
IDU2 as HIV risk         
No 435 87.7 136 84.5 299 89.3 0.1 
Yes 61 12.3 25 15.5 36 10.7  
Substance Abuse        
No  350 70.6 118 72.4 232 69.3 0.4 
Yes 146 29.4 43 27.6 103 30.7  
Access to Care Characteristics 
Insurance Status        
Public3 126 25.9 51 31.7 75 23.1 0.003 
None 168 34.6 39 24.2 129 39.7  
Private/Other 192 39.5 71 44.1 121 37.2  
Distance to ID4 clinic (miles)        
<50   130 26.3 37 23 93 27.8 0.2 
>50 365 73.7 124 77 241 72.2  
Clinical Characteristics 
       
AIDS5 Diagnoses        
No  343 69.2 119 73.9 224 66.9 0.1 
Yes 153 30.8 42 26.1 111 33.1  
CD4 cells/uL        
<200    257 57.6 62 47.7 195 61.7 0.006 
200-350        81 18.2 24 18.5 57 18.0  
>350 108 24.2 44 33.9 64 20.3  
Mean HIV RNA (log10) (sd) 4.9 (1.0) 4.7 (1.0) 4.8 (0.97) 0.9 
Mental Illness        
No  398 80.2 135 83.9 263 78.5 0.2 
Yes 98 19.8 26 16.1 72 21.5 
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Diagnosis to treatment 
(months) 
<1   56 12.5 20 13.3 38 12.1 0.5 
1-3 112 24.9 31 20.5 81 27.2  
3-24 177 39.4 64 42.4 113 37.9  
    >24 104 23.2 36 23.8 68 22.8  
Treatment Characteristics 
       
HAART category8        
n2pib/n3pib/n2pi2 99 20.0 8 5.0 91 27.2 0.001 
n2nnrti/n3nnrti 192 38.7 42 26.1 150 44.8  
n2pi/n3pi 134 27.0 85 52.8 49 14.6  
n2nnrtipi/nnrtipi 40 8.1 23 14.3 17 5.1  
3nrti 31 6.3 3 1.9 28 8.4  
Other Laboratory 
Parameters 
       
ANC6 (109/L)        
Normal 268 62.2 73 59.4 195 63.3 0.4 
Abnormal 163 37.8 50 40.6 113 36.7  
Hemoglobin (g/dL)        
Normal 195 41.1 57 46 138 44.8 0.8 
Abnormal 237 54.9 67 54 170 55.2  
Creatinine (mg/dL)        
Normal 462 93.2 153 95 309 92.2 0.2 
Abnormal 5134 6.8 8 5 26 7.8  
7ALT U/L        
Normal 338 81.1 93 80.2 245 81.4 0.8 
Abnormal 10079 18.9 23 19.8 56 18.6  
 
 
* p values comparing early to current periods 
1MSM=Men who have sex with Men; 2IDU=Injection Drug Use; 3Public insurance= 
Medicaid/Medicare;  
4
 ID= University of North Carolina Infectious Disease; 
5AIDS=Acquired Immune Deficiency Syndrome; 6ANC=Absolute Neutrophil Count 
7ALT=Alanine amino transferase 
 
HAART Category8 
n2pib=2 NRTIs + boosted PI 
n3pib= 3 NRTIs + boosted PI  
n2pi2 = 2 NRTIs + 2 PIs 
n2nnrti= 2NRTIs + 1NNRTI 
n3nnrti = 3NRTIs + 1NNRTI 
n2pi= 2 NRTIs + 1 PI 
n3pi= 3 NRTIs + 1 PI 
n2nnrtipi-=2 NRTIs + 1PI + 1NNRTI 
nnrtipi=  1PI + 1NNRTI 
3nrti= 3 NRTIs 
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Table A 2.2: Baseline sample characteristics comparing subjects with virologic 
success to subjects without virologic success, restricted to complete cases 
 Total Viral Load  
<400 c/mL 
Viral Load  
>400 c/mL 
p 
value* 
 N (496) % N (387) % N (109) %  
Primary Exposure 
       
No Trial 327 65.9 242 62.5 85 78.0 0.003 
Trial 169 34.1 145 37.5 24 22.0  
Demographic and 
Behavioral Characteristics 
       
Age (years)        
 <40   273 55 206 53.2 67 61.5 0.1 
>40 223 45 181 46.8 42 38.5  
Gender/sexual preference        
MSM1/Bisexual men     175 35.3 138 35.6 37 33.9 0.9 
Heterosexual men 136 27.4 105  27.1 31 28.5  
Heterosexual women 185 37.3 144 37.2 41 37.6  
Race        
Black       298 60.1 225 58.1 73 67 0.1 
Non Black     198 31.9 162 41.9 36 33  
IDU2 as HIV risk         
No 435 87.7 340 87.9 95 87.2 0.8 
Yes 61 12.3 47 12.1 14 12.8  
Substance Abuse        
No  350 70.6 280 72.4 70 64.2 0.1 
Yes 146 29.4 107 27.6 39 35.8  
Access to Care 
Characteristics 
       
Insurance Status        
Public3 126 25.9 96 25.4 30 27.8 0.7 
None 168 34.6 129 34.1 39 36.1  
Private/Other 192 39.5 153 40.5 39 36.1  
Distance to ID4 clinic (miles)        
<50   130 26.3 99 25.7 31 28.4 0.6 
>50 365 73.7 287 74.3 78 71.6  
Clinical Characteristics 
       
AIDS5 Diagnoses        
No  343 69.2 266 68.7 77 70.6 0.7 
Yes 153 30.8 121 31.3 32 29.4  
CD4 cells/uL        
<200    257 57.6 201 56.9 56 60.2 0.6 
200-350        81 18.2 63 17.9 18 19.4  
>350 108 24.2 89 25.2 19 20.4  
Median HIV RNA (log10) (sd) 4.9 (1.0) 4.7 (1.0) 4.9 (0.9) 0.05 
Mental Illness        
No  398 80.2 312 80.6 86 78.9 0.7 
Yes 98 19.8 75 19.4 23 21.1 
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Diagnosis to treatment 
(months) 
       
<1   56 12.5 42 12.0 14 14.3 0.001 
1-3 112 24.9 94 26.8 18 18.4  
3-24 177 39.4 148 42.2 29 29.6  
      >24 104 23.2 67 19.1 37 37.8  
Treatment Characteristics 
       
HAART Initiation Year        
1996-99 161 32.5 121 31.3 40 36.7 0.3 
2000-06 335 67.5 266 68.7 69 63.3  
HAART category8        
n2pib/n3pib/n2pi2 99 20.0 84 21.7 15 13.8 0.001 
n2nnrti/n3nnrti 192 38.7 155 40.1 37 33.9  
n2pi/n3pi 134 27.0 89 23.0 45 41.3  
n2nnrtipi/nnrtipi 40 8.1 36 9.3 4 3.7  
3nrti 31 6.3 23 5.9 8 7.3  
Other Laboratory 
Parameters 
       
ANC6 (109/L)        
Normal 268 62.2 217 62.9 51 59.3 0.5 
Abnormal 163 37.8 128 37.1 35 40.7  
Hemoglobin (g/dL)        
Normal 195 41.1 162 46.8 33 38.4 0.2 
Abnormal 237 54.9 184 53.2 53 61.6  
Creatinine (mg/dL)        
Normal 462 93.2 359 92.8 103 94.5 0.5 
Abnormal 5134 6.8 28 7.2 6 5.5  
7ALT U/L        
Normal 338 81.1 274 81.6 64 79.0 0.6 
Abnormal 10079 18.9 62 18.4 17 21.0  
 
 
* p values comparing persons with viral load <400 to >400 
1MSM=Men who have sex with Men; 2IDU=Injection Drug Use; 3Public insurance= 
Medicaid/Medicare;  
4
 ID= University of North Carolina Infectious Disease; 
5AIDS=Acquired Immune Deficiency Syndrome; 6ANC=Absolute Neutrophil Count 
7ALT=Alanine amino transferase 
 
HAART Category8 
n2pib=2 NRTIs + boosted PI 
n3pib= 3 NRTIs + boosted PI  
n2pi2 = 2 NRTIs + 2 PIs 
n2nnrti= 2NRTIs + 1NNRTI 
n3nnrti = 3NRTIs + 1NNRTI 
n2pi= 2 NRTIs + 1 PI 
n3pi= 3 NRTIs + 1 PI 
n2nnrtipi-=2 NRTIs + 1PI + 1NNRTI 
nnrtipi=  1PI + 1NNRTI 
3nrti= 3 NRTIs
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Table A 2.3: Comparison of antiretroviral treatment regimens provided within clinical 
trials to antiretroviral treatment regimens provided within clinical care, 1996-2006 
 
 Trial Non Trial 
HAART regimen* Freq. Percent Freq. Percent 
n2pib/n3pib/n2pi2 53 10.31 75 33.48 
n2nnrti/n3nnrti 205 39.88 83 37.05 
n2pi/n3pi 196 38.13 22 9.82 
n2nnrtipi/nnrtipi 26 5.06 29 12.95 
3nrti 34 6.61 15 6.7 
Total 514 100 224 100 
      
  
 
 
 
 
HAART regimen* 
n2pib- 2 NRTIs + boosted PI 
n3pib- 3 NRTIs + boosted PI  
n2pi2 - 2 NRTIs + 2 PIs 
n2nnrti- 2NRTIs + 1NNRTI 
n3nnrti - 3NRTIs + 1NNRTI 
n2pi- 2 NRTIs + 1 PI 
n3pi- 3 NRTIs + 1 PI 
n2nnrtipi- 2 NRTIs + 1PI + 1NNRTI 
nnrtipi-  1PI + 1NNRTI 
3nrti- 3 NRTIs 
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Table A 2.4: Comparison of antiretroviral treatment regimens provided 
in the early HAART period to antiretroviral treatment regimens provided 
in the current HAART period 
HAART regimen* 
Early Period 1996-99 
n=266 
% 
Current Period 2000-06 
n=438 
% 
 
Total 
n=738 
% 
 
n2pib/n3pib/n2pi2 12 116 128 
  4.51 24.58 17.34 
n2nnrti/n3nnrti 69 219 288 
  25.94 46.4 39.02 
n2pi/n3pi 148 70 218 
  55.64 14.83 29.54 
n2nnrtipi/nnrtipi 32 23 55 
  12.03 4.87 7.45 
3nrti 5 44 49 
  1.88 9.32 6.64 
 
 
* HAART regimen 
n2pib- 2 NRTIs + boosted PI 
n3pib- 3 NRTIs + boosted PI  
n2pi2 - 2 NRTIs + 2 PIs 
n2nnrti- 2NRTIs + 1NNRTI 
n3nnrti - 3NRTIs + 1NNRTI 
n2pi- 2 NRTIs + 1 PI 
n3pi- 3 NRTIs + 1 PI 
n2nnrtipi- 2 NRTIs + 1PI + 1NNRTI 
nnrtipi-  1PI + 1NNRTI 
3nrti- 3 NRTIs 
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Table A 2.5: Study number, study design and official title of clinical trials included in this study  
Study  Study Design Official Title 
ACTG 
384 
Treatment, Double-Blind, Pharmacokinetics Study Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual 
Nucleosides in Initial Therapy of HIV Infection 
ACTG 
388 
Treatment, Open Label, Safety Study A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in 
Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir 
(IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/mm3 or Greater 
Than or Equal to 80,000 HIV RNA Copies/Ml in Plasma 
ACTG 
5015 
Treatment, Efficacy Study A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-
Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-
Disease Progression Associated With Aging 
ACTG 
5073 
Treatment, Randomized, Open Label, Uncontrolled, 
Parallel Assignment, Safety/Efficacy Study 
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent 
Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered 
Under Direct Observation 
ACTG 
5095 
Treatment, Active Control, Safety/Efficacy Study Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing 
Regimens for the Initial Treatment of HIV Infection 
ACTG 
5142 
Treatment, Randomized, Open Label, Active 
Control, Parallel Assignment, Safety/Efficacy Study 
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz 
Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for 
HIV-1 Infection 
ACTG 
5164 
Diagnostic, Randomized, Open Label, Active 
Control, Parallel Assignment, Efficacy Study 
A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute 
Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy 
ACTG 
5175 
Treatment, Randomized, Open Label, Active 
Control, Parallel Assignment, Efficacy Study 
A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily 
Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing 
Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals From Resource-
Limited Settings (PEARLS) Trial 
ACTG 
5202 
Other, Randomized, Active Control, Parallel 
Assignment, Safety/Efficacy Study 
A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in 
Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or 
Abacavir/Lamivudine in Antiretroviral-Naive Subjects 
Abbott 
M97 
Treatment, Randomized, Double Blind (Subject, 
Caregiver, Investigator, Outcomes Assessor), 
Parallel Assignment, Safety/Efficacy Study 
Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in 
Antiretroviral Naive HIV-Infected Patients 
Gilead 
903 
Treatment, Parallel Assignment A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-
Naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in 
Combination With Lamivudine and Efavirenz Versus Stavudine, Lamivudine, and Efavirenz 
Gilead 
934 
Treatment, Randomized, Open Label, Active 
Control, Parallel Assignment, Safety/Efficacy Study 
Phase 3/Randomized/Open-Label Study of the Treatment of Antiretroviral-Naive HIV-1-
Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination 
With Efavirenz vs. Combivir (Lamivudine/Zidovudine) and Efavirenz 
KLEAN 
Treatment, Randomized, Open Label, Dose 
Comparison, Parallel Assignment, Safety/Efficacy 
Study 
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of 
GW433908 (700mg BID) Plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir 
(400mg/100mg BID) When Administered in Combination With the Abacavir/Lamivudine 
(600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected 
Adults Over 48 Weeks 
 
